A histomorphometric study of the effect of Afriplex GRT(TM) on the pancreas, liver and kidney of rats fed a high-fat diet by Layman, Jodie
A HISTOMORPHOMETRIC STUDY OF THE EFFECT OF AFRIPLEX 




Thesis presented in fulfilment of the requirements for the degree 
Master of Science in Morphological sciences at 
Stellenbosch University 
Supervisor: Prof S.H. Kotzé 
Co-supervisor: Dr N. Chellan 
Faculty of Medicine and Health Sciences 
December 2018 
The financial assistance of the National Research Foundation (NRF) towards this research is hereby 
acknowledged. Opinions expressed, and conclusions arrived at, are those of the author and not 
necessarily to be attributed to the NRF. 
ii 
DECLARATION 
By submitting this thesis electronically, I declare that the entirety of the work contained therein 
is my own, original work, that I am the sole author thereof (save to the extent explicitly 
otherwise stated), that reproduction and publication thereof by Stellenbosch University will not 
infringe any third party rights and that I have not previously in its entirety or in part submitted 
it for obtaining any qualification. 
December 2018 
Copyright © 2018 Stellenbosch University
All rights reserved
Stellenbosch University  https://scholar.sun.ac.za
iii 
ABSTRACT 
Obesity causes a wide range of disorders including insulin resistance, hepatic steatosis as well 
as renal glomerular and tubular pathology. These disorders are typically associated with 
oxidative stress and inflammation. Rooibos, Aspalathus linearis, is a South African plant which 
has antioxidative, anti-inflammatory, antilipidemic, and antihyperglycemic properties as 
shown in vivo and in vitro. Afriplex GRT™ is an unfermented green rooibos extract which is 
postulated to have enhanced effects compared to fermented rooibos, mostly due to its high 
aspalathin content. The present study aimed to determine the ameliorative effects of Afriplex 
GRT™ on the histomorphometry of the pancreas liver and kidney in a diet-induced obese rat 
model.  
Male Wistar rats (N=28) were randomly sorted into four study groups (n=7) namely, control 
(C), GRT fed control (GRT), high-fat diet (HFD) and HFD supplemented with GRT (HFD-
GRT). Animals were either fed a control feed or a HFD which contained fat, cholesterol and 
fructose. Animals in the GRT and HFD-GRT groups were supplemented with Afriplex GRT™ 
at a concentration of 60 mg per kg body mass per day. Body mass, and pancreatic, liver and 
kidney mass were determined after which samples were processed to wax. Tissues were 
sectioned at 4 – 5 µm in thickness and stained using haematoxylin and eosin for analysis by a 
histopathologist. Immunohistochemistry using anti-insulin and anti-glucagon double antibody 
labelling was performed on the pancreas. Other staining techniques included Masson’s 
trichrome, Gordon and Sweet’s reticulin impregnation and periodic acid Schiff. Additionally, 
frozen sections of the liver and pancreas were stained using Oil red O for lipid infiltration. 
Morphometric techniques included area, diameter, radii, point counting and ratios.  
Body mass significantly decreased in the HFD-GRT group compared to the HFD group. 
Pancreas and kidney mass decreased significantly in the HFD-GRT group compared to the C-
group, however liver mass significantly increased in both HFD groups. Islet area and β-cell 
area significantly decreased in the HFD-GRT group compared to all three control groups 
however, a greater number of islets was observed. Hepatic steatosis and liver pathology were 
reduced in the HFD-GRT group compared to the HFD group. Renal space and the proximal 
convoluted tubules were decreased in the HFD-GRT compared to C-group as indicated by 
trends. Additionally, a trend was observed in the arcuate artery media to lumen ratio which was 
increased in the GRT group compared to the HFD group.  
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Similar to the present study, a decrease in body mass has been observed with fermented rooibos 
and its polyphenols in HFD-fed animals. In the HFD-GRT group, increased islets per section 
area and smaller islet areas are associated with increased insulin secretion, which suggests 
improved glucose tolerance. This study suggests that Afriplex GRT™ may effectively reduce 
hepatic steatosis, an effect previously seen in studies on fermented rooibos and rooibos 
polyphenols. More in-depth studies on the effects of Afriplex GRT™ in the kidney are needed, 
potentially for a longer study period. Therefore, Afriplex GRT™ has observable ameliorative 
effects on the histomorphology of the liver and the pancreas; the effects on the kidney requires 
further investigation. 
  




Vetsug veroorsaak 'n groot verskeidenheid van afwykings, wat insluit insulienweerstandigheid, 
hepatiese steatosis, asook renale glomerulêre en tubulêre patologie. Hierdie afwykings word 
tipies geassosieer met oksidatiewe stres en inflammasie. Rooibos, Aspalathus Linearis, is 'n 
Suid-Afrikaanse plant wat anti-oksidatiewe, anti-inflammatoriese, anti-lipidemiese en anti-
hiperglukemiese eienskappe toon, volgens in vivo en in vitro studies. Daar word gepostuleer 
dat Afriplex GRT™, wat 'n ongefermenteerde groen rooibos uittreksel is, ‘n versterkte effekt 
toon in vergelyking met gefermenteerde rooibos, hoofsaaklik as gevolg van die hoë aspalatien 
inhoud. Die doel van die huidige studie was om die verbeterende effekte van Afriplex GRT™ 
op die histomorfometrie van die pankreas, lewer en nier in ‘n dieet-geïnduseerde obesitiet 
rotmodel vas te stel.  
 
Manlike Wistar rotte (N = 28) was verdeel in vier studiegroepe (n = 7) naamlik, kontrole groep 
(K), kontrole GRT groep (GRT), hoëvet diet groep (HVD) en HVD met GRT groep (HVD- 
GRT). 'n Beheer voer of 'n HVD (wat vet, cholesterol en fruktose bevat) was vir rotter gevoer. 
Die voer van rotte in die GRT en HVD-GRT groepe was aangevul met Afriplex GRT™, met 
'n konsentrasie van 60 milligram per kg liggaamsmassa per dag. Liggaamsmassa as ook 
pankreas, lewer en nier massa was bepaal, waarna weefsel in was verwerk was. Weefsels was 
gesny teen ‘n 4 - 5 μm dikte en gekleur met hematoksilien en eosien vir analise deur 'n 
histopatoloog. Immunohistochemiese kleuring vir anti-insulien en anti-glukagon was op die 
pankreas uitgevoer. Masson’s trichrome, Gordon en Sweet’s retikulien saturasie, en periodic 
acid Schiff was ook gedoen. Verder was bevrore snitte van die lewer en pankreas met Oil red 
O gekleur vir lipied infiltrasie. Morfometriese tegnieke het ingelsuit in area, deursnee, radius, 
punt telling en verhoudings. 
 
Liggaamsmassa het aansienlik afgeneem in die HVD-GRT-groep in vergelyking met 
die HVD-groep. Pankreas- en niermassa het aansienlik afgeneem in die HVD-GRT-groep in 
vergelyking met die K-groep, maar die lewermassa het aansienlik toegeneem in beide HVD-
groepe. In die HVD-GRT-groep het die eiland- en beta-selgebied aansienlik afgeneem in 
vergelyking met al drie beheergroepe, maar 'n groter aantal eilandjies is waargeneem. 
Hepatiese steatosis en lewerpatologie was in die HVD-GRT-groep verlaag in vergelyking met 
die HVD-groep. Renale spasie en die proksimale kronkelbuisies is in die HVD-GRT verlaag 
in vergelyking met K-groep soos aangedui deur tendense. Daarbenewens was 'n tendens 
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waargeneem in die arcuate arterie media tot lumen verhouding wat in die GRT groep vergroot 
is in vergelyking met die HVD groep. 'n Vermindering in liggaam gewig, vergelykbaar met die 
huidige studie, was geassosieer met gefermenteerde rooibos en sy polyfenole in die HVD- 
gevoerde diere. In die HVD-GRT-groep het die toenemende eilandjies per area en aantal 
kleiner eilandjies per area gelei tot ‘n verhoogde insulienafskeiding, wat verbeterde 
glukosetoleransie aandui. Hierdie studie dui daarop dat Afriplex GRT™ hepatiese steatosis 
effektief kan verminder, 'n effek wat voorheen gesien is in studies oor gefermenteerde rooibos 
en rooibos polifenole. Meer in-diepte studies oor die gevolge van Afriplex GRT™ in die nier 
is nodig, ideal vir 'n langer tydperk. Dus, Afriplex GRT™ het waarneembare verbeterende 
effekte op die histomorfologie van die lewer en die pankreas. Hierdie effekte op die nier vereis 
verdere ondersoek. 
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Aspalathus linearis, commonly known as rooibos, is a South African plant with proven effects 
on metabolic related disorders. Rooibos may be prepared in its fermented, traditional form or 
unfermented green form. The effects of fermented rooibos, its extracts and individual 
polyphenols in vitro and in vivo are established. These effects include: decreasing 
hyperglycaemia (Kawano et al., 2009; Son et al., 2013; Kamakura et al., 2015), improving 
hyperlipidaemia and liver steatosis (Beltran-Debon et al., 2010), reducing oxidative stress 
(Joubert et al., 2004), cardiovascular disease (Pantsi et al., 2011), inflammation (Ajuwon et al., 
2013), and nephroprotective effects (Alhoshani et al., 2017). More recently, the use of 
unfermented rooibos in research is gaining popularity, mostly due to its high aspalathin content.  
 
Afriplex GRT™ is a laboratory standardized unfermented rooibos extract developed by 
African Plant Extracts Pty, Ltd. (Afriplex). Improvement of vascular function, myocardial 
insulin resistance and mitochondrial function, liver antioxidant profile, liver and body mass 
reducing properties of Afriplex GRT™ have been determined in two unpublished masters 
theses on the same experimental animals (Kroukamp, 2018; Maqeda, 2018). Organs from the 
same studies were studied on a histological level to determine whether the effects of Afriplex 
GRT™ reflected on histology and morphology of the pancreas, liver and kidney.  
 
Obesity is a chronic, lifestyle-related metabolic disorder which results from the imbalance of 
caloric intake and energy expenditure. An unhealthy sedentary lifestyle (Wang et al., 2016) 
and unhealthy diet are associated with obesity, which promotes excessive deposition of visceral 
and ectopic white adipose tissue (Noeman et al., 2011). Obesity is associated with insulin 
resistance, type two diabetes mellitus, fatty pancreas and liver disease, hypertension and 
chronic kidney disease. Many of these effects can be replicated in animal models to study the 
mechanisms behind these disorders. Disorders commonly observed in animal models include: 
increased body and organ mass (Buettner et al., 2007; Beltran et al., 2011), alterations in islet 
morphology, number and size (Slavin et al., 2010; Oliveira et al., 2014), hepatic steatosis 
(Catta-Preta et al., 2011; Schultz et al., 2013), glomerulomegaly and tubular dysfunction in the 
kidney (Altunkaynak et al., 2008; Stemmer et al., 2012). As obesity and its associated disorders 
increase, the need to comprehend the consequences of these conditions and provide solutions 
is vital. Animal models of metabolic disorders have been studied extensively with several 
herbal extracts, including fermented rooibos (Beltran et al., 2011; Mathijs et a., 2014; 
Sanderson et al., 2014; Sasaki et al., 2018); however, the potential effects of an unfermented 
green rooibos extract in a diet-induced obese rat model requires further investigation.  
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Therefore, the present study, aimed to determine the effects of Afriplex GRT™, on the 
histomorphology of pancreas, liver and kidney of rats fed a HFD. Morphometric and 
histological study of pancreatic islets, liver hepatocytes, the renal corpuscle, proximal 
convoluted tubules and arcuate arteries of the kidney were performed. In addition, study of 
Afriplex GRT™ as a protective supplement will determine whether the protective effects of 
Afriplex GRT™ are visible on a histomorphometric level. 
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2.1 OBESITY: THE GLOBAL EPIDEMIC 
Obesity is defined as constant caloric intake which exceeds energy expenditure and results in 
the excessive formation of white adipose tissue (WAT) (Akoum et al., 2011; Sanderson et al., 
2014). The World Health Organization (WHO) reported that obesity has more than doubled 
since 1980 (Obesity & Overweight., 2016). According to the Organization for Economic Co-
operation and Development (OECD), globally one in two adults and almost one in six children 
are overweight and or obese. Further they stated that more than one in four adults in countries 
including South Africa, are obese (Obesity update, 2017). South Africa has the highest obesity 
rate in sub-Saharan Africa (The Heart and Stroke foundation of South Africa, 2016). Statistics 
from the South African demographics survey (2016) revealed that 31% of males and 68% of 
females were reported to be obese, and that the Western Cape is the obesity capital of South 
Africa.  
 
Obesity results in ectopic and visceral WAT infiltration and accumulation which may result in 
fatty deposition in the liver, skeletal muscle, heart (Noeman et al., 2011) and pancreas (Ou et 
al., 2013). Insulin resistance, chronic kidney disease, hepatic steatosis (Stemmer et al., 2012), 
diabetes mellitus, and hypertension (Sanderson et al., 2014) are all obesity associated disorders 
of major public health concern (Park et al., 2012). Many of these disorders fall under the term 
‘metabolic syndrome’ which is characterised by insulin resistance, glucose intolerance, 
hypertension, systemic inflammation, atherogenic dyslipidaemia and abdominal obesity 
(Roberts & Sindhu, 2009). These disorders are usually associated with inflammation (Park et 
al., 2012) and oxidative stress (Roberts & Sindhu, 2009; Beltran-Debon et al., 2011; Noeman 
et al., 2011; Favero et al., 2013).  
 
2.1.1 Diet-induced obesity (DIO) 
Obesity may be induced in rodents and other animal models by dietary, neuroendocrine or 
genetic means (Noeman et al., 2011). Consumption of a HFD is the major risk factor in 
metabolic disorders and is central to disorders linked to obesity (Beltran et al., 2011; Akoum 
et al., 2011). The adverse effects associated with an HFD occur due to the imbalance between 
energy use and calorie intake. The purpose of diet-induced obesity in rodents is to replicate the 
Western-diet (Lozano et al., 2016) and lifestyle associated with obesity (Wang et al., 2016). In 
animal studies, a HFD usually consists of corn-starch, sucrose, fructose or maltodextrose, a 
source of fat e.g. lard or soybean oil, casein, minerals and vitamins as well as a source of fibre 
(Warden & Fisler, 2008). In contrast, chow diets can be defined as high-carbohydrate or -fibre 
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diets as they usually consist of corn, oats or ground wheat, alfalfa and soybean meals, vitamins 
and minerals, vegetable oil and a protein source such as fish (Warden & Fisler, 2008; Pellizon 
& Ricci, 2018). Several organs are negatively affected by HFD consumption the pancreas, liver 
and kidney are organs frequently injured by metabolic disorders associated with unhealthy 
lifestyles and eating habits. The anatomy, histology and the effects obesity on the pancreas, 
liver and kidney will be discussed briefly. 
 
2.2 PANCREAS  
2.2.1 Anatomy and histology  
The pancreas is a lobulated organ located in the abdominal cavity consisting of two main 
functional units, exocrine and endocrine glands (Young et al., 2006). The exocrine portion 
consists of the pancreatic acini which secrete enzymatic juices to assist digestion while the 
endocrine portion, consisting of pancreatic islets (Islet of Langerhans), and is responsible for 
glucose homeostasis (Young et al., 2006). Figure 2.2 illustrates the morphology and 
histological arrangement of the rodent pancreas; the micrograph shows an anti-insulin (pink) 
and anti-glucagon (brown) labelled β- and α-cells, respectively. This organ consists of more 
exocrine tissue than endocrine tissue, with the latter only making up 2 to 4 % of the total organ 
volume (Williams et al., 2016).  
 
 
Figure 2.1: Morphology of the rodent pancreas. (A) macroscopic anatomy of the pancreas and 
(B) micrography of pancreatic histology double antibody labelled with anti-insulin and anti-
glucagon (B). The rodent pancreas is generally divided into four regions the upper duodenal (UD), lower 
duodenal (LD), gastric (G) and splenic regions (S) (Elayat et al., 1995). Histologically, the pancreas consists of 
endocrine pancreatic islets and exocrine acinus. The pancreatic islets area labelled with anti-glucagon (brown) 
and anti-insulin (pink) for α- and β-cells. Figure A adapted from Elayat et al. (1995). Micrography by Jodie 
Layman. 




The rat pancreas extends from the end of the duodenal fold towards the gastro-splenic omentum 
(Greene, 1955; Baker et al., 1979). The rat pancreas may be characterized into four regions 
namely the duodenal upper (UD) and lower (LD), splenic(S) and gastric (G)regions (Elayat et 
al., 1995).The human pancreas consists of five regions, the head, neck, body, tail and uncinate 
process. Similair to the rodent pancreas, the head of the human pancreas is encircled by the 
duodenum and the tail extends towards the spleen. Both pancreatic islets of rodents and humans 
consist of four cell types: alpha (α-) secreting glucagon cells, beta (β-) secreting insulin, delta 
(δ-) secreting somatostatin and pancreatic polypeptide (pp-) cells. Different species each have 
their own distinct arrangement of the cell types however the functions of cells are consistent 
(Quesada, Todorova & Soria, 2006). In rodents pancreatic islets are made up of 60-80% β-cells 
and 10-15% α-cells mantle (Quesada, Todorova & Soria, 2006; Steiner et al., 2010). 
Structurally, rodent islets cells arrange themselves with a β-cells core and a mantle of α-cells 
with interspersed δ- and pp-cells. In human pancreatic islets, α-cells make up the majority 
forming a central core (Steiner et al., 2010) while the remainder of cells are scattered 
throughout the islets. Collectively these cell types control glucose homeostasis. After a meal 
insulin is secreted to assist glucose absorption into cells all over the body. Thereafter, glucagon 
assists secretion of glucose from storage sites to maintain cell function. However, in metabolic 
disorders this balance is compromised especially in obese individuals who consume copious 
amounts of unhealthy foods. In these individuals, hyper secretion of insulin occurs, and 
glucagon is under secreted. Hyperglycaemia persists due to peripheral insensitivity to insulin 
leading to further injury. This has particular effects on the β-cells which have very few 
endogenous antioxidants (Sakuraba et al., 2002; Kim et al., 2009). The exocrine portion also 
experiences injury as the increase in nutrients leads to intra-pancreatic adipocyte deposition. 
Therefore, both damage to the endocrine and exocrine portions can be problematic.  
 
2.2.2 The effects of obesity on the pancreas 
As of 2017, four hundred and twenty-five million people are estimated to be living with 
diabetes mellitus (Sasaki et al., 2018). Type two diabetes mellitus (T2D) is associated with 
obesity and is characterised by high blood glucose (Slavin et al., 2010; Nolan et al., 2011), 
peripheral insulin resistance, and deficient insulin secretion from the pancreas (Sasaki et al., 
2018). Alterations in pancreatic islets including: increased islet number, size and morphology 
as well as insulin secretion are associated with obesity (Slavin et al., 2010). Generally, obese 
individuals consume copious amounts of carbohydrates which places significant strain on 
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glucose balance which is maintained by glucagon secreted by pancreatic islet α- cells and 
insulin secreted by β- cells. As a result of these eating patterns, pancreatic β-cells experience 
excessive stimulus to secrete insulin. Insulin resistance results in impaired insulin signalling to 
the liver for the inhibition of glucose release, and stimulation of glucose uptake by the 
peripheral organs (Reaven et al., 2005). As peripheral insulin resistance in the liver, muscle, 
adipose tissue, kidney and other organs (Reaven et al., 2005) is present, excessive glucose 
levels persist in the blood (hyperglycaemia). To attenuate this, β-cells secrete more insulin 
(hyperinsulinemia) however, after prolonged hyperglycaemia and insulin resistance, β-cells 
apoptosis (Donath et al., 1999), and resultant decrease in β-cells mass and function occurs and 
results in T2D.  
 
Diabetes mellitus and insulin resistance are associated with changes in islet size and number 
(Slavin et al., 2010) β-cells mass, and function (Nolan et al., 2011). Animals fed an HFD 
usually present with larger islets (Fraulob et al., 2010) which suggests increased hormone 
secretion. However, smaller islets are associated with increased insulin secretion in both rodent 
and human islets (Kim et al., 2009; Kotze, 2015). Similar to islets, β-cells also increase with 
the presence of a HFD (Falcoa et al., 2016) however, HFDs are associated with β-cell related 
lipotoxicity which may result in β-cell apoptosis (Mathijs et al., 2014). In pancreatic islets, β-
cells secrete insulin whereas α-cells oppose insulin by secreting glucagon (Young et al., 2006) 
when blood glucose is low. Glucagon targets the liver to increases glucose production 
(Hanhineva et al., 2010). The balance between glucagon and insulin secretion is altered in 
obesity associated disorders like insulin resistance and diabetes mellitus. Previously in a 
diabetic rat model, increased body and organ mass as well as degenerated pancreatic islets, 
vacuolized and degranulation of β-cells was observed in control and HFD fed animals 
(Anyakudo & Omotayo, 2015). 
 
Obesity results in fat infiltration in many organs including the pancreas where it is known as 
non-alcoholic fatty pancreas disease (NAFPD). The latter is characterized by increased 
pancreas mass which compromises pancreatic function (Fraulob et al., 2010). Pancreatic mass 
is usually increased in obese human individuals (Yagahashi, 2016), or in animals exposed to a 
HFD (Fraulob et al., 2010; Carter et al., 2014; Anyakudo & Omotayo, 2015). However, 
pancreas mass is rarely reported in human autopsy due to the difficulty with which it can be 
accurately dissected as it has obscure borders (Yagahashi et al., 2016; Yu & Wang, 2017). The 
presence of pancreatic steatosis is associated with insulin resistance and pancreatic islet related 
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lipotoxicity (Mathijs et al., 2014; Yagihashi, 2016). Intra- and interlobular fat accumulation 
associated with chronic HFD exposure in rodentsts and results in damage to pancreatic 
architecture and islets morphology (Fraulob et al., 2010; He et al., 2010; Carter et al., 2014), 
fibrosis as well as inflammatory cell infiltration (Ou et al., 2013). Histology and biochemical 
measurements are used frequently to assess pancreatic steatosis. However, as the pancreas is 
prone to rapid autolysis and difficult to clearly dissect no precise pattern of pancreatic steatosis 
has been clearly defined (Yu & Wang, 2017). 
 
The excessive lipid infiltration and deposition associated with NAFPD leads to the death and 
replacement of the pancreatic acinar cells with adipose tissue known as pancreatic steatosis 
(intralobular) and has a suggested role in T2DM (Yagahashi, 2016; Ou et al., 2013). 
Furthermore, NAFPD compromises pancreas function due to the release of local fat-derived 
cytokines which may result in inflammation (Fraulob et al., 2010). Consensus as to whether 
the alterations in the pancreas are due to fat infiltration associated with insulin resistance or β-
cell function in humans is still unknown (Yu & Wang, 2017). The presence of fatty pancreas 
diseases promotes chronic pancreatitis, exacerbates acute pancreatitis and may lead to 
pancreatic cancer (Ou et al., 2013). Figure 2.2 describes the link between the liver, pancreas 
and visceral adipose tissue in insulin resistance and hyperglycaemia and how they contribute 
to NAFLD and NAFPD. 
  





Figure 2.2: Summary of the effects of a diet high in fat on pancreas, liver and visceral adipose 
tissue (VAT). In the pancreas β-cell death occurs as a result of intracellular triglyceride (TG) 
accumulation due to the inhibition of β-oxidation (fatty acid catabolism). β-cell death results in 
decreased insulin secretion and the replacement of pancreatic tissue with adipose tissue (pancreatic 
steatosis). In the liver, hepatocytes are overwhelmed by the increase in free fatty acids (FFA), TG 
synthesis is favoured and increased intracellular accumulation of lipids and the release of very low-
density lipoproteins (VLDL) occurs. Furthermore, within hepatocytes de novo lipogenesis is triggered 
further increasing TG production. Increased VLDL secretion from the liver increases intracellular TG 
accumulation in the pancreas. The presence of hepatic steatosis increases hyperglycaemia as hepatic 
insulin resistance is present and hepatic glucose balance is lost (hepatocyte failure). Visceral adipose 
tissue (VAT) stores increase due to increased FFA, insulin resistance (IR) and hyperglycaemia. The 
VAT stores secrete FFA triggered by IR, and adipocytokines. (Adapted fromYagihashi, 2016). 
 
Non-alcoholic fatty pancreas disease is associated with non-alcoholic fatty liver disease 
(NAFLD); ectopic fat infiltration in the liver parenchyma (Ou et al., 2013). Non-alcoholic fatty 
liver disease (NAFLD) is the clinical manifestation of insulin resistance associated with 
chronic intake of a HFD (Schultz et al., 2013). Study of NAFPD is relatively new and was only 
recently established in both animal and human studies (Della Corte et al., 2015). Insulin and 
glucagon, hormones secreted by the pancreas, maintains the balance between lipid metabolism 
in the liver (Campbell et al., 2006) further emphasizing the link between the liver and pancreas 
(Yu & Wang, 2017) especially in metabolic disorders. Synergistic effects of NAFLD and 
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NAFPD have shown effects on β-cell function and glucose metabolism (Della Corte et al., 
2015) however, further investigation is required to confirm this.  
 
2.3 LIVER 
2.3.1 Anatomy and histology  
The liver is a largest organ found in the abdominal cavity of humans and rats (Young et al., 
2006). The rodent liver is divided into four main lobes namely: the median lobe, a right lateral 
lobe, a small caudate lobe and a large left lateral lobe (Baker et al., 1979; Malarkey et al., 2005; 
Shi et al., 2015) (Figure 2.3 B). The liver is involved in glucose, lipid and protein storage and 
synthesis (Young et al., 2006) and acts as the main organ responsible for eliminating and 
detoxifying toxins (Ajuwon et al., 2013). Glycogenesis, glycogenolysis and gluconeogenesis 
are glucose processing pathways in the liver which help maintain glucose balance. These 
pathways are also responsible for metabolizing carbohydrates to fatty acids and triglycerides 
(Young et al., 2006; Hanhineva et al., 2010) which is important for plasma lipoprotein 
production. Lipids are usually used to synthesize plasma lipoproteins (very-low, low- and high-
density lipoproteins) and oxidised to triglycerides for energy (Hanhineva et al., 2010). In 
comparison to humans, rats do not have a gallbladder the organ responsible for storing bile 
which assists fat digestion. In rats, their bile ducts anastomose and secrete bile directly into the 
duodenum (Suckhow et al., 2005). Some proteins such as those involved with haemostasis and 
fibrinolysis as well as albumin and other hormone and pro-hormones are produced and secreted 
by the liver (Young et al., 2006; Kierszenbaum & Tres, 2015). In addition to nutrient 
homeostasis, protein storage and synthesis, the liver filters the blood and plays significant role 
in neutralizing toxic of substances (Ajuwon et al., 2013).  
 




Figure 2.3: Illustration of the liver of humans (1) and rodents (2) and a representative micrograph 
of the rodent liver (3). The human liver is divided into two anatomical lobes, right (R) and left (L), 
and two accessory lobes, caudate and quadrate (not shown).The rodent liver lobes may be divided into 
the (A) median lobe (right and left), (B & E) right lateral lobe, (C) left lateral lobe(largest) and the 
caudate lobe (D). (* indicates the oesophagus). C) The histology of the liver, with hepatocytes radiating 
from the central veins with interspersed sinusoids. (CV) central vein, (PT) portal triad. Bar indicates 
500μm. (1) Schematic illustration of liver (Netter et al., 2005). (2) Adapted from Baker et al., 1979. (3) 
Micrography by Jodie Layman. 
 
The liver histologically has various cell types namely, hepatocytes, Kupffer cells, stellate cells 
and endothelial cells (sinusoidal and biliary) (Malarkey et al., 2005; Young et al., 2013; 
Pellicoro et al., 2014). Hepatocytes make up the parenchymal portion of the liver which 
accounts for 80% of the liver volume. Furthermore, these cells make up 66% of the total cells 
within the tissue and are responsibly for metabolism and secretion of various substances 
(Sherwood, 2013). Hepatocytes are polyhedral shaped cells, with a large central nucleus which 
may be mono- or bi-nucleated (Gupta, 2000). Kupffer cells are the residing macrophages of 
the liver located frequently in the periportal regions and the sinusoids (Young et al., 2006). The 
Space of Disse is located between the sinusoids and the hepatocytes. Specialized cells namely 
the stellate cells are found in the space of Disse and are the main determinants of fibrogenesis, 
cirrhosis and regeneration of the liver (Malarkey et al., 2005).  
 
Hepatic lobules are the structural and functional units of the liver. Three arrangements of 
hepatic lobules exist: classic, portal and acinus (Malarkey et al., 2005). The classical lobule 
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consists for five to six portal triads surrounding a central terminal hepatic vein. A portal vein, 
hepatic artery and bile duct form the portal triads, a specialized trio forming the “border“ of 
liver lobules. Portal lobules involve three central veins where the bile canaliculi join into a 
single bile duct (Malarkey et al., 2005; Kierszenbaum & Tres, 2015). Hepatic physiology and 
pathology are best described by the third type of hepatic lobule, the hepatic acinus. The hepatic 
acinus consists of a portal triad and two central veins on either side. The acinus splits this area 
into three zones: zone one (periportal), two (midzonal) and three (centrilobular) (Malarkey et 
al., 2005; Young et al., 2006; Kierszenbaum & Tres, 2015). 
 
2.3.2 The effects of obesity on the liver  
The current obesity epidemic is associated with increased lipid infiltration in the liver, known 
as a chronic liver disease namely, Non-alcoholic fatty liver disease (NAFLD). Non-alcoholic 
fatty liver disease (NAFLD) is the most common liver disease globally with a prevalence of 
10-45% (Brunt et al., 2011; Wang et al., 2016). A full spectrum of disease falls under the 
umbrella term of NAFLD, which includes hepatic steatosis, steatohepatitis, cirrhosis and 
hepatocellular carcinoma. Atherosclerosis, metabolic syndrome, insulin resistance and T2DM 
are all associated with NAFLD. As a result of the synergistic effects of metabolic disorders, 
NAFLD can assist early detection of metabolic disorders in normal mass individuals (Ou et al., 
2013). NASH is the more aggressive form of NAFLD associated with metabolic syndrome and 
obesity which may lead to cirrhosis and hepatocellular carcinoma. NASH is characterized by 
inflammation, steatosis and progressive fibrosis as well as a decrease in fatty acid oxidation 
and an increase in lipid oxidation (Choi et al., 2013; Wang et al., 2016).  
 
  




Figure 2.4: Representative micrographs of normal liver (A) and two livers with fatty disease (B 
& C). In comparison to (A), (B) shows severely ballooned hepatocytes with microvesicular steatosis. 
(C) shows the presence of inflammatory foci and some microvesicular steatosis. Sinusoids are obscured 
due to hepatocyte ballooning in both (B) and (C). Black arrows indicate microvesicular steatosis. Dash 
lines encircle hepatocyte in (A) & (B) and inflammatory foci in (C). Micrography by Jodie Layman. 
 
Hepatic steatosis is closely associated with metabolic syndrome and obesity. High-fat diet 
induced hepatic steatosis is characterized by a decrease in fatty acid oxidation as well as an 
increase in lipid oxidation (Choi et al., 2013). Normally, the liver recruits’ fatty acids for β-
oxidation in the mitochondria of hepatocytes. Additionally, it esterifies fatty acids to glycerol 
for storage as triglycerides or packages them as very low-, low-or high-density lipoproteins 
(Brown & Goldstein, 1986). Steatosis occurs upon the imbalance of hepatic lipid intake and 
synthesis to triglycerides within hepatocytes which is greater than beta-oxidation and export of 
plasma lipoproteins and results in increased liver mass (Fraulob et al., 2010; He et al., 2010). 
Lipid infiltration becomes evident as micro- and or macrovesicular steatosis within the tissue. 
Due to the excess lipid intake, lipid containing vacuoles become present in the hepatocyte 
cytoplasm (microvesicular) which with the continuation of excessive lipid intake vacuoles 
increase, enlarge and displace the nucleus (macrovesicular); (Wang et al., 2016). The presence 
of microvesicular steatosis is not a key pathological marker in NAFLD, although focal regions 
of microvesicular steatosis associated with macrovesicular steatosis is (Wang et al., 2016). In 
fatty liver disease, the micro- and macrovesicular vacuoles may narrow and even occlude the 
hepatic sinusoids (Farrel et al., 2006). The degree of hepatic steatosis is directly correlated with 
fibrosis and inflammation (Wang et al., 2016). Fibrosis indicates disease progression and is 
observed in more than 80% of people diagnosed with NASH (Farrel et al., 2006). 
 
Liver pathology associated with obesity usually includes hyperlipidaemia, increased lipid 
peroxidation and oxidative stress with the reduction of antioxidants and glutathione levels in 
the liver (Beltran-Debon et al., 2010; Noeman et al., 2011; Park et al., 2012). Park et al. (2012) 
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showed increased triglyceride and total cholesterol infiltration in the liver associated with HFD 
feeding. The presence of hepatic steatosis in HFD fed rat and mice models is common (Catta-
pretta et al., 2011; Levene et al., 2011;Schults et al., 2013). In addition, tumour promotion in 
the liver has been linked to liver inflammation caused by an HFD (Park et al., 2010). 
 
2.4 KIDNEY  
2.4.1 Anatomy and histology  
The kidneys are two bean shaped organs attached to the posterior body wall responsible for 
filtering the blood and producing urine. In the rat, the right kidney and its suprarenal gland are 
located more cranially than the left (Greene, 1955). The rat kidney has one calyx, specialized 
fornixes of the renal pelvis helps to concentrate urine in the papilla and well-developed renal 
pyramids. The functional unit of the kidney is the nephron; made up of the renal corpuscle 
(glomerulus and Bowman’s capsule), proximal and distal convoluted tubules, loop of Henle 
ending in collecting ducts (Young et al., 2006). The kidneys form part of the urinary system 
which functions to filter fluids from blood and excrete wastes. Specifically, the kidney is 
responsible for water homeostasis by filtering glucose, sodium and other small molecules 
(Kierszenbaum & Tres, 2015).  
 
The glomerulus is a lobulated capillary mass within a specialized thin walled capsule lined 
with squamous epithelium, the Bowman’s capsule (Kierszenbaum & Tres, 2015). The capsule 
has 2 layers a visceral layer in contact with the glomerulus which has podocytes and a parietal 
layer which covers Bowman’s capsule. The space between these layers is known as the renal 
or urinary space. The proximal convoluted tubule is a characteristic structure in most rodents. 
It has cuboidal shaped cells lining the lumen of the tubule with large round nuclei 
(Kierszenbaum & Tres, 2015). The PCT is stained with periodic acid Schiff stain due to is 
glycogen rich brush border. In contrast to PCTs, distal convoluted tubules (DCT), have larger 
lumens and more nuclei. As DCTs lack a brush border they are not stained with periodic acid 
Schiff (PAS). 





Figure 2.5: Morphology of the kidney (A) and a photomicrograph of the rat kidney cortex (B). 
(G) Glomerulus, (P) Proximal convoluted tubule, (D) Distal convoluted tubule (40x). Bar represents 
500 μm. Micrograph by Jodie Layman. 
 
The kidney is supplied with blood via a single renal artery. Renal arteries split into interlobar 
arteries which in turn branch into arcuate arteries. The arcuate arteries are found at the 
corticomedullary junction (the border between the cortex and medulla) (Reddi et al., 2001). 
Arcuate arteries give rise to interlobular arteries which branch and give rise to afferent 
arterioles which form the glomerular capillary network (Kierszenbaum & Tres, 2015). 
 
2.4.2 The effects of obesity on the kidney 
Chronic obesity has numerous consequences on the structural and functional components of 
the kidney. Functionally, tubular reabsorption is increased by activation of the sympathetic 
nervous system and the renin-angiotensin systems leading to a higher blood pressure (obesity 
related hypertension) (Hall et al., 1998). Hypertension is defined as systolic and diastolic blood 
pressure greater than 140/90 mmHg. Primary and secondary causes of hypertension are well 
defined. Primary causes are related to behavioural and lifestyle related choices while secondary 
hypertension is related to abdominal obesity (Ritchie & Connel, 2007). Activation of the renin-
angiotensin (RAAS) system plays an important role in blood pressure regulation and fluid 
regulation in the kidney (Young et al., 2006). These changes physiologically lead to structural 
alterations in the arterial system and parts of the kidney.  
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Structurally, obesity results in increased renal vasodilation, glomerulosclerosis, a greater 
glomerular surface area, mesangial thickening and podocyte injury (Altunkaynak et al., 2008; 
Stemmer et al., 2012). Collectively this may be termed obesity-related glomerulopathy and is 
usually associated with proteinuria (Ekonoyan, 2011; Stemmer et al., 2012). Furthermore, 
other obesity associated pathologies include increased glomerular filtration rate, renal 
hypertrophy, glomerulomegaly and increased albuminuria which may lead to renal cell 
carcinoma (Ekonoyan, 2011). In obese individuals, increased visceral adipose tissue especially 
around the kidneys causes increased renal pressure. This pressure affects renal tubular 
absorption especially sodium reabsorption and affects the excretion of sodium in the urine.  
 
Obesity exacerbates the onset and progression of nephropathy and preneoplasia in the kidneys 
(Stemmer et al., 2012). In diabetic individuals, decreased renal mass is common and is 
associated with renal disease progression (Tobar et al., 2013). In contrast, Crinigan et al. (2015) 
reported increased renal mass following a short term HFD of six weeks. Similarly, increased 
renal mass was observed in C57BL/6J mice fed a HFD over a period of 52-weeks (Van Der 
Heijden et al., 2015). Chronic exposure to a HFD produced pronounced nephropathy in the 
corticomedullary region of the kidney in male wistar rats which were sensitive or resistant to 
diet induced obesity for eleven-months (Stemmer et al., 2012). They reported nephropathy 
which include dilated glomerular blood vessels, proteinaceous casts, thickened basement 
membranes, interstitial inflammation, shedding and exfoliation of proximal tubular cells in the 
tubular lumen, hyperplasia, increased cell number and multi-layered tubules as well as 
glomerulosclerosis and tubule-interstitial fibrosis (Stemmer et al., 2012). Altunkaynak et al. 
(2008) studied the morphometric parameters and structure of kidneys exposed to a HFD. They 
reported glomerular capillary and blood vessel dilation, glomerular sclerosis, tubule defects, 
thickened basement membranes and fibrosis (increased connective tissue). They concluded that 
a significant relationship existed between structural changes in the kidney and fatty diet intake 
(Altunkaynak et al., 2008). Thus, the effects of a HFD may negatively effect on the structure 
and function of the kidney. 
 
Although obesity negatively effects the pancreas, liver and kidney, the main cause is increased 
oxidative stress, inflammation and the inability to maintain homeostasis.  
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2.5  OXIDATIVE STRESS AND OBESITY 
Obesity is associated with oxidative stress and inflammation (Roberts & Sindhu, 2009; Beltran-
Debon et al., 2011; Noeman et al., 2011; Favero et al., 2013). Oxidative stress occurs when 
the production of free radicals overwhelms the endogenous antioxidant systems (Roberts & 
Sindhu, 2009) resulting in pathology. Oxygen, nitrogen, chlorine and sulphur are sources of 
free radicals. Reactive oxygen and nitrogen species (ROS and RNS) specifically include 
superoxide, hydroxyl radical and hydrogen peroxide while RNS include nitric oxide and 
peroxynitrite radicals (Pizzino et al., 2017).  
 
Physiologically, ROS forms part of many normal processes in the human body (Rahal et al., 
2013). Mitochondria are the main cell organelles responsible for the production of ROS as a 
by-product of normal cellular aerobic metabolism. In the mitochondria, reduction reactions 
occur which remove electrons from oxygen producing free radicals, oxygen containing 
molecules with unequal electrons. Production of ROS can be from both exogenous and 
endogenous sources however ROS is primarily produced by the mitochondrial electron 
transport chain (Pizzino et al., 2017). Exogenous sources of ROS include ultraviolet radiation, 
pharmaceutical drugs, pollutants, toxins and foods. Other sources of ROS include xanthine 
oxidase, NADPH oxidase and eNOS coupling. The production of ROS can be deleterious or 
beneficial as it forms part of cellular metabolism, cell signalling (Burton & Jauniax, 2011), 
apoptosis, defence from pathogens as mediators of inflammation (Roberts & Sindhu, 2009) 
and inducing cell division (Ajuwon et al., 2013). However, excess production of ROS in 
pathophysiological conditions can result in oxidative stress in the form of degradation of lipids, 
proteins, cell membranes and nucleic acids (Roberts & Sindhu, 2009; Pizzino et al., 2017).  
 
Pro-oxidants are highly reactive ions or atoms (free radicals) which have an unpaired electron 
in their outer orbital. These free radicals are unstable and usually react with macromolecules 
to attempt to complete their outer orbital (Burton & Jauniax, 2011). When binding to 
macromolecules, they induce oxidation and the production of oxidative species. Antioxidants 
are endogenous or exogenous molecules which counteract the production and elimination of 
ROS to reduce oxidative stress (Pizzino et al., 2017). Endogenous antioxidants include the 
enzymatic molecules superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase 
(GPx) (Roberts & Sindhu, 2009; Pizzino et al., 2017). In the event of excessive ROS 
production, the addition of exogenous antioxidants like vitamin C, E and A, β-carotene, metals 
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and plant polyphenols can be beneficial (Pizzino et al., 2017). Although, excess antioxidants 
can also result in oxidative stress, thus the pro-oxidant-antioxidant balance is important.  
 
The complete absence of ROS or the addition of too many antioxidants can result in tissue 
damage. Pancreatic β-cells are particularly sensitive to oxidative stress as they lack sufficient 
antioxidant enzymes, specifically GPx and SOD (Abdollahi et al., 2004). Thus, in the event of 
type two diabetes mellitus or hyperglycaemia β-cells experience significant strain which may 
lead to reduced β-cells mass. The liver is responsible for detoxification of various substances, 
thus oxidative imbalance is likely to occur. An oxidant, tert-butyl hydroperoxide (t-BHP), once 
metabolized by hepatocytes can result in lipid peroxidation which decreases membrane fluidity 
and results in damage to nucleic acids (Ajuwon et al., 2013). The kidney is highly susceptible 
to ROS induced injury, as a result of the high content of polyunsaturated fatty acids which 
when exposed to ROS, undergo lipid peroxidation (Pizzino et al., 2017).  
 
Plant polyphenols from fruit, vegetables and teas due to their antioxidant rich polyphenol 
content can be beneficial in conditions associated with oxidative stress (Ajuwon et al., 2013; 
Rahal et al., 2013; Pizzoni et al., 2017). Globally a surge in metabolic disorders is occurring 
linked to unhealthy diets. Diets high in fruits and vegetables have shown promising effects 
against oxidative stress as a result of their antioxidant content (Rahal et al., 2013; Pizzoni et 
al., 2017). In addition, the use of teas has shown promising effects due to the antioxidant rich 
polyphenol content they contain (Ajuwon et al., 2013). Aspalathin found in rooibos, 
contributes 43% of the total antioxidant capacity (Joubert et al., 2005).  
 
2.6 ASPALATHUS LINEARIS (ROOIBOS) DISTRIBUTION AND BOTANY  
Rooibos, Aspalathus linearis (Brum.f.) Dahlgren (family Fabaceae; tribe Crotalariae) is an 
indigenous South African plant with more than 270 endemic species. This polymorphic shrub 
has various wild forms each with their own characteristic morphology and geographical 
distribution. A. linearis is found in the Cederberg wilderness extending into the Citrusdal, 
Niewoudtville (Beelders et al., 2012) and Clanwilliam regions of the Western Cape (Joubert et 
al., 2008). Generally, A. linearis has bright green coloured needle-like leaves which turn red-
brown once they are bruised (Morton, 1983). The leaves have short internodes (Joubert & de 
Beer, 2011) with “pea-shaped” yellow flowers usually found in clusters (the flowers affect the 
taste of the tea and are thus removed) on long slender stems (Morton, 1983). As many 
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morphological adaptations of rooibos exist, rooibos plants may occur in straggling forms less 
than 30 cm to erect bushes up to 1.35-2 m in height. Figure 2.5 describes two types of rooibos 
and the forms used in research of its health benefits.  
 
Figure 2.6: The types of Rooibos, Aspalathus linearis, fermented and unfermented used in various 
studies.  
 
2.6.1 Rooibos history and commercialization 
Rooibos was first listed as a medicinal African plant by Watt and Breyer-Brandwijk in 1932 
however, no applications of the plant were specified. Carl Thunberg, a European Botanist 
visited the Western cape in 1722 where he observed the Khoi san people using rooibos as a 
beverage (Joubert et al., 2008). Later, Benjamin Ginsberg, a Russian merchant, also observed 
the Khoi san harvesting, processing and brewing the plant which he later commercialized in 
1904 (Joubert & de Beer, 2011).  
 
During World War II, the early Dutch settlers drank rooibos as an alternative to Oriental (black) 
tea which was very expensive and unavailable. After World war II, the rooibos market 
collapsed as more convenient forms of Oriental tea’s (tea bags) and inexpensive coffees 
became available (Joubert et al., 2008). The rooibos industry has since recovered and become 
a household brand based on its caffeine-free and low-tannin content (Joubert et al., 2008). The 
popularity of rooibos has increased globally (Marnewick et al., 2011) with increasing consumer 
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interest in natural antioxidant containing products (Beelders et al., 2012) as well as its pleasant 
flavour (Joubert & de Beer, 2011).  
 
Initially, the quality of rooibos `was not standardized, thus the composition of polyphenols, 
and antioxidants reaching consumers was not guaranteed. This prompted the establishing of 
the Rooibos Tea Control Board to ensure the quality and marketing of the tea (Joubert & de 
Beer, 2011). The health benefits associated with rooibos have been linked to its phenolic 
composition (Joubert & de Beer, 2011; Muller et al., 2017). Rooibos is believed to have several 
medicinal and health promoting properties however many of them are yet to be scientifically 
substantiated (Joubert & de Beer, 2011; Marnewick et al., 2011) 
 
Due to the proposed medicinal effects of rooibos its development into extracts and products 
has become increasingly popular. The first use of rooibos as a supplement was in the treatment 
of a one-year old child who suffered from colic. The mother Annique Theron used rooibos to 
heat the milk and found the condition of the child dramatically improved. (Morton, 1983). This 
finding resulted in the development of a cosmetic care range (Joubert & de Beer, 2011). Since 
then, the use of fermented rooibos for extracts and supplements in foods and beverages is well 
established. In various forms, rooibos is added to beverages, foods, cosmetic products, tablets, 
and supplements (Joubert & de Beer, 2011). Unfermented rooibos products have now become 
more common and are available commercially. Freshpak™ has launched its green rooibos 
variant available in most stores in the Western cape.  
 
2.6.2 Processing Rooibos 
Rooibos processing originated from the Khoi san people who harvested rooibos by chopping 
the shoots with an axe, mashing them with a mallet, fermented and sun-dried the bruised 
fragments in hollows of stones (Joubert et al., 2008). Processing of rooibos has been 
modernized in terms of the machinery and methods used but the principle remains the same 
(Joubert & de Beer, 2011). The current processing procedure follows the same sequence 
beginning with comminution or shredding of the leaves. Thereafter, the leaves are bruised to 
initiate browning and left to ferment (sweat) and dry out in the open. Tea makers believed 
sunlight was essential for the development of the characteristic red colour (Joubert, 1996; 
Joubert & de Beer, 2011). The addition of tea pasteurization was introduced in the 1980’s to 
ensure low microbial activity after a Salmonella contamination scare, however, this process 
may jeopardize the content of essential rooibos flavonoids (Joubert & de Beer, 2011). 




General rooibos processing results in the production of the traditional red (fermented) rooibos 
product. During fermentation, enzymatic and structural changes occur which result in the 
characteristic red-brown colour and taste as well as a substantial decrease in the phenolic 
composition (Canda et al., 2014) especially the antioxidant potential (Vilano et al., 2010). 
Throughout the fermentation process a significant amount of the dihydrochalcone, aspalathin, 
is lost resulting in only 7% of the original aspalathin content remaining in the fermented rooibos 
product (Joubert, 1996; Canda et al., 2014). Fermentation, processing techniques and genetic 
variation all affect the antioxidant (flavonoid) content and phenolic composition of rooibos 
(Marnewick, 2014).In the 1990’s the Agricultural research council (ARC) proposed a new 
method of processing to produce an unfermented rooibos product, rich in antioxidants (Vilano 
et al., 2010) especially aspalathin (De Beer et al., 2016) namely unfermented (green) rooibos.  
 
Unfermented (green) rooibos is processed in conditions to maintain the green colour and 
polyphenol content lost during bruising or traditional processing techniques (Joubert & de 
Beer, 2011). Unfermented rooibos contains several polyphenols of which aspalathin, 
nothofagin, Z-2-(β-D-Glucopyranoloxy)-3-phenylpropenoic acid (PPAG), quercetin as well as 
orientin and iso-orientin all have promising medicinal properties (Muller et al., 2017). A 
comparison of fermented and unfermented rooibos polyphenol values per 100 g of leaf solids 
is shown in Table 2.1.  
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Table 2.1: The mean content of rooibos polyphenols and resultant antioxidant capacity per 100 g 
of leaf solids of fermented and unfermented rooibos leaves &stems. Adapted from Beelders et al. 
(2012) & Marnewich et al. (2014) 
Chemical group Polyphenols Fermented 
rooibos* 
(g/100 g leaf 
solids) 
Unfermented 
rooibos (g/100 g 
leaf solids) 
Dihydrochalcones Aspalathin 0.64±0.17 12.4±0.1 
Nothofagin 0.10±0.03 1.7±0.16 
Flavones Orientin, 0.92±0.05 0.81±0.08 
Iso-orientin, 1.3±0.08 1.3±0.16 
Vitexin 0.19±0.02 0.18±0.02 
Iso-vitexin 0.20±0.01 0.23±0.03 
Flavanols Quercetin 0.94±0.16 0.91±0.12 








Hydroxycinnamic acid Ferulic acid 0.09±0.04 Not detected 
Total polyphenol capacity# 
(mg gallic acid equivalents) 
73.43±1.79 106.46±2.14 
Total antioxidant capacity$ 1537.60±27.40 2093.57±50.20 
* Fermented rooibos based on one cup = 200 mL prepared by steeping one rooibos tea bag in 200 mL fresh 
boiled water. # Folin-Ciocalteu methods measured against gaelic acid equivalents(GAE).  
$ Based on the oxygen radical absorbance capacity (± Standard deviation) of ten samples. 
 
Aspalathin is a cyclic dihydrochalcone C-C glycoside which has only been found in rooibos, 
more in the unfermented form than the fermented form. During traditional rooibos processing 
aspalathin is converted to vitexin (Vilano et al., 2010), orientin and iso-orientin via its 
flavanone analogues (Krafczyk & Glomb, 2008; Krafczyk et al., 2009). A patented method of 
vacuum-drying has been found to produce green rooibos with a high aspalathin content 
however at this point it is too expensive to commercialize (Joubert & de Beer, 2011). Other 
methods proposed to ensure high aspalathin content include a rapid extraction process, low 
temperatures and pH, as well as the exclusion of oxygen during fermentation to hinder loss of 
the compound. Several countries, with Japan at the forefront, have produced patents for green 
rooibos extracts using these methods. Aspalathin is extremely sensitive to heat, oxidation, light 
and varying pH and thus orientin and iso-orientin are more stable and easier to quantify. 
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Aspalathin has negligible bioavailability (Joubert & de Beer, 2011); thus, its combination with 
other rooibos polyphenols may be essential for its efficacy  
 
2.6.3 Bioavailability of Rooibos and its extracts 
The use of green rooibos extracts and purified isolated polyphenol compounds as commercial 
products and as treatments in research is dependent on its bioavailability. Absorption, 
metabolism, excretion and distribution of polyphenols in the gastrointestinal system are 
influenced by several factors (Manach et al., 2005). These factors specifically affect the ability 
of rooibos in vivo. namely the medium by which the compound is administered ad libitum in 
e.g. in drinking water, mixed in feed, jelly blocks or orally gavage (Muller et al., 2017). The 
method by which rooibos is administered (in vitro or in vivo) is essential to its ability to have 
the required affects. Many in vitro studies have published remarkable results which cannot 
always be reciprocated in in vivo studies. Furthermore, the form in which the compound is 
given for example in water-based extracts, laboratory prepared extract powders or as purified 
isolated compounds affect its ability to have the required effects (Snijman et al., 2007; Kawano 
et al., 2009; Perold, 2009; Beltran et al., 2011; Canda et al., 2014).  
 
Many authors agree that the purified polyphenol compounds are effective in various disorders 
(Snijman et al., 2007; Kawano et al., 2009; Perold, 2009) however the rooibos extract, works 
synergistically to produce the beneficial effects (Canda et al., 2014). The use of a pure 
compound may allow easier transport across the intestinal epithelium. Even thou polyphenols 
may reach the intestinal epithelium intact its interaction with the intestinal microflora may 
result in its transformation to its metabolites. Thus, the isolation of a single polyphenolic 
compound may not be as effective as the whole extract (Beltran-Debon et al., 2011; Joubert & 
de Beer, 2011; Canda et al., 2014; Kamakura et al., 2015).  
 
When rooibos is ingested, its polyphenols are predominantly metabolized in the liver and colon 
(Vilano et al., 2010).Most rooibos flavonoids may be passed from the small intestine to the 
large intestine where they interact with the colonic microflora (Kreuz et al., 2008). The 
interaction with the microflora results in the release of the aglycones of aspalathin and isomers 
of iso-orientin which may be detected in urine and/or plasma (Muller et al., 2017). The 
absorption and metabolism of aspalathin has been elaborated on due to the increasing interest 
in its use in research and health products. As aspalathin does not undergo extensive processing 
and employs a concentration gradient to traverse the intestinal epithelium by paracellular 
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means (Courts & Williamson, 2009; Bowles et al., 2017) thereafter it enters the portal venous 
system (Stalmach et al., 2009).  
 
The absorption of aspalathin has been evaluated in animal and human studies and will be 
outlined briefly below (Kreuz et al., 2008; Courts & Williamson, 2009; Stalmach et al., 2009; 
Courts & Williamson, 2015). A study using caco-2 cells model noted that C-glucosyl 
flavonoids such as aspalathin cross the intestinal epithelium by passive diffusion without 
metabolism (de-glycosylation) (Kreuz et al., 2008; Courts & Williamson, 2015). The 
absorption of aspalathin in vitro using caco-2 cells in a monolayer showed an improved 
aspalathin bioavailability when ingested as a green rooibos extract versus an isolated 
compound (Huang, du Plessis, du Preez, Hamman, & Viljoen, 2008). This places further 
emphasis on the theory that the synergistic effects of rooibos as an extract and not as individual 
polyphenols are what make it viable (Muller et al., 2017).  
 
The absorption of aspalathin in vivo was first evaluated in pig studies by Kreuz et al. (2008). 
They fed the animals an aspalathin-enriched green rooibos extract and measured the amount of 
aspalathin in blood and urine after seven and 11 days. They concluded that aspalathin did not 
require de-glycosylation to be absorbed and detected aspalathin conjugated to methyl, 
glucuronic acid or both in urine samples but no aspalathin or its metabolites could be detected 
in plasma (Kreuz et al., 2008). The explanation for the low concentration of aspalathin in 
plasma samples is as a result of affinity for plasma proteins (Muller et al., 2017) however, 
aspalathin can be detected in plasma if a large dose of green rooibos is ingested as was the case 
in a human study (Breiter et al., 2011). 
 
Human studies have also evaluated the bioavailability of green rooibos metabolites found in 
urine (Stalmach et al., 2009), as well as plasma (Breiter et al., 2011). Stalmach et al. (2009) 
reported that aspalathin metabolites were the major excretory products 0-24 hours after 
consumption of fermented and unfermented rooibos. The main metabolite excreted after green 
rooibos ingestion was O-methyl-aspalathin-O-glucuronide, whereas, eriodyctiol-O-glucosides 
was the main metabolite excreted after fermented rooibos consumption. Aspalathin metabolites 
can be detected in urine within 5h of consumption whereas fermented rooibos metabolites 
between 5-12 h. This indicates different sites of absorption; for green rooibos, the small 
intestine, and fermented rooibos, the large intestine (Muller et al., 2017). Breiter et al. (2011), 
found no significant rise in plasma antioxidant activity after the consumption of unfermented 
Stellenbosch University  https://scholar.sun.ac.za
26 
 
rooibos (tea or extract form) but trace amounts of unchanged rooibos polyphenols such as 
aspalathin were detected. The urine analysis identified methylated aspalathin as the major 
excretory product, with many other forms of aspalathin and nothofagin being detected (Breiter 
et al., 2011). 
 
2.6.4 The effects of fermented and unfermented Aspalathus linearis  
The benefits of rooibos can be attributed to the major flavonoids it contains, which have been 
shown to have several promising effects including: antioxidant (Sanderson et al., 2014; 
Monsees & Opuwari, 2016), cancer modulating (Marnewick et al., 2009; Joubert & de Beer, 
2011; Canda et al., 2014), antimutagenic (Canda et al., 2014; Snijman et al., 2007), anti-
histaminic (Morton, 1983), hepatoprotective (Beltran-Debon et al., 2011), immune system 
modulating (Vilano et al., 2010), anti-inflammatory (Ajuwon et al., 2013; Scholms et al., 2013; 
Canda et al., 2014), antidiabetic (Muller et al., 2012; Ajuwon et al., 2013), dermatological 
(Shindo & Kato, 1991), anti-hypouricemic (Najafian et al., 2016), hypoglycaemic effects 
(Kawano et al., 2009; Beltran-Debon et al., 2011; Mathjis et al., 2014; Kamakura et al., 2015), 
anti-lipogenic effects (Beltran-Debon et al., 2011; Sanderson et al., 2014), anti-viral and anti-
atherosclerotic effects (Canda et al., 2014), and antimicrobial effects (Hübsch et al., 2014). 
Rooibos has also been said to improve appetite, reduce anxiety, promotes sleep and soothe 
digestive disorders (Morton, 1983). Anti-obesity effects have previously been shown in vivo 
(Beltran-Debon et al., 2011) and in vitro (Sanderson et al., 2014). The effects of a high 
aspalathin green rooibos extract in an obese model has not yet been evaluated. Table 2.2. 
illustrates a summary of metabolic effects associated with unfermented rooibos and rooibos 
polyphenols  
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Table 2.2: The use of unfermented rooibos extracts in various models adapted from (Muller et al., 2017). 
Rooibos type/ extract/ 
infusion 






Skin carcinogenic mouse 
model  
Reduced incidence and volume of tumours reduced oxidative 
stress  






In vitro, COS-1 cells 
transfected with baboon 
DNA 
Reduced output of steroids compounds (4-fold) and reduced 
the precursors of aldosterone and cortisol 




Anti-diabetic In vitro and in vivo, C2Cl2 
and Chang cells and Wistar 
rats respectively  
Reduction in high blood sugar, increased ability for glucose 
uptake, inhibited α-glucosidase 
Muller et al, 
2012 
Green, aspalathin 
enriched extract and a 
fermented extract 
Anti-diabetic In vitro, insulin resistant 
C2Cl2 muscle cells 





 Male wistar rats standard 
control diet 
Liver mass was significantly increased in 5% unfermented 
rooibos. No effect on absolute liver and kidney mass or 
kidney mass expressed as a percentage of body mass. Liver 




Green rooibos extract Anti-diabetic L6 myotubes and RIN-5F 
pancreatic β-cells and obese 
diabetic KK-Ay rat model 
L6 myotubes: promoted glucose uptake via AMPK and AKT 
phosphorylation RIN-5F: protected against AGE induced 






 Female wistar rats Increased serum creatinine, no changes in histology of the 
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2.6.4.1 Anti-diabetic effects of rooibos 
Standard type 2 diabetes treatment includes metformin and diet control, an alternative strategy 
is that of green rooibos. Two strategies have been proposed as control strategies for 
postprandial glucose elevation, one being agents which are able to inhibit α-glucosidase and 
hydrolases enzymes found in the brush border of the small intestine (Muller et al., 2012). An 
alternate strategy is the inhibition of glucose reabsorption by glucose transporters in the kidney 
(Jesus et al., 2017; Sasaki et al., 2018). Muller et al. (2012) demonstrated the use of green 
rooibos as an effective agent to inhibit yeast α-glucosidase. Using HPLC, they determined the 
extract with the highest inhibitory aspalathin activity and used it in STZ-induced diabetic rats. 
Their extract showed a sustained and effective lessening effect on blood glucose comparable 
to that of metformin (Muller et al., 2012). Aspalathin and nothofagin, major polyphenols in 
green rooibos, have shown the ability to alter glucose reabsorption in the kidney further 
suggesting a role for green rooibos extracts as antidiabetic compounds (Jesus et al., 2017; Lui 
et al., 2015). 
 
A rooibos polyphenol of interest in anti-diabetic research is Z-2-(β-D-Glucopyranoloxy)-3-
phenylpropenoic acid (PPAG) which has shown anti-diabetic properties. In a HFD- rat model 
PPAG effectively protected against pancreatic β-cell mass loss as well as β-cell endoplasmic 
reticulum (ER) stress by increasing anti-apoptotic molecule expression (BCL2). Furthermore, 
PPAG prevented hyperglycaemia in obese rats (Mathijs et al., 2014). Another study made use 
of PPAG in an in vitro Chang cell model and in rats fed a high-fat and sucrose/fructose diet. 
There they showed an improvement in glucose uptake by the cells and increased expression of 
glucose regulating proteins: glucokinase, glucose transporters (GLUT) 1 & 2, insulin receptors, 
peroxisome proliferator- activated receptor alpha (PPARα) and suppressor of cytokine 
signalling (SOCS) in the liver of the rats. In the same study, improved glucose tolerance and 
fasting glucose concentration were observed (Muller et al., 2013). Lastly, in Balb/c mice 
exposed to STZ, PPAG effectively protected β-cells from apoptosis and maintained expression 
of anti-apoptotic molecule BCL-2 (Himpe et al., 2016). 
 
Aspalathin, as an isolated polyphenol compound has been associated with antidiabetic effects 
in several in vitro and in vivo models. Its analogues, orientin and iso-orientin have been linked 
to antidiabetic effects as well as cardioprotective and anti-inflammatory effects. A few authors 
have reported antidiabetic properties with aspalathin (Kawano et al., 2009; Muller et al., 2012; 
Son et al., 2013; Mazibuko et al., 2015). One such study was on type-two diabetic mice where 
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aspalathin was shown to potentially suppresses fasting blood glucose and improve glucose 
tolerance (Son et al., 2013). A study by Kawano and colleagues (2009) showed increase 
glucose break-down and insulin secretion in cultured RIN-5F pancreatic β-cells in vitro with 
aspalathin. Similarly, Kamakura et al. (2015) made use of an in vitro β-cell model and showed 
that both the use of an aspalathin-enriched green rooibos extract and aspalathin as an isolated 
compound was effective against cell death and ROS-induced cell dysfunction and suppressed 
fasting blood glucose in vivo (Kamakura et al., 2015). Iso-orietin has also been associated with 
anti-diabetic effects such as decreasing high blood sugar (Sezik et al., 2015) and enhancing 
insulin signalling and genetic expression. Furthermore, orientin was able to improve the blood 
lipid profile (Sezik et al., 2015) and inflammatory conditions by regulating inflammatory 
cytokines (Wedler et al., 2014). 
 
Mazibuko et al. (2013) showed anti-diabetic effects of fermented and unfermented rooibos in 
palmitate-induced insulin resistant C2C12 muscle cells in vitro. Rooibos effectively resolved 
the palmitate induced injury and nullified its effects on mitochondrial activity, glucose 
consumption and cell ATP levels (Mazibuko et al., 2013). In a study of adipocytes (3T3-L1 
cells) in combination aspalathin and a green rooibos extract relieved the palmitate induced 
insulin resistance, suppressed protein expression of nuclear factor kappa beta (NF-κB), 
adenosine monophosphate (AMP)- activated protein kinase (AMPK), and insulin receptor and 
increased protein kinase B (AKT). The green rooibos extracts increased protein expression of 
GLUT4, a glucose channel, and the expression of peroxisome proliferation receptor while the 
isolated aspalathin increased carnitine palmitoyl transferase 1 (Mazibuko et al., 2015). These 
effects collectively propose that green rooibos extracts which contain aspalathin may possess 
hypoglycaemic properties which may reduce the effects of a HFD. 
 
2.6.4.2 Hepatoprotective and Hepatotoxic effects of rooibos 
The hepatoprotective effects of rooibos may be related to its effects on liver steatosis. Beltran-
Debon et al. (2011) showed rooibos effectively protected the liver from lipid retention in the 
presence of excessive calorie intake induced by a HFD. In the same study, fermented rooibos 
showed hypolipidemic effects and notable changes in lipid metabolism in rats fed a high-fat 
diet supplemented with an aqueous rooibos extract (Beltran-Debon et al., 2011). Additionally, 
they observed decreased hyperlipidaemia with rooibos supplementation in HFD animals 
however, no significant effects in the control animals. This suggests that rooibos only works in 
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severely metabolically disturbed conditions (Rodriguez-Sanabria et al., 2010; Beltran-Debon 
et al., 2011) especially in mice fed a diet mimicking the western diet (Joubert & de Beer, 2011).  
 
Rooibos ameliorated the effects of the HFD on the liver by decreasing the lipid storage and 
helping to break down the stored fat (Beltran-Debon et al., 2011). Another study similarly 
reported anti-lipogenic properties using a fermented rooibos extract. They concluded that the 
addition of fermented rooibos effectively inhibited adipocyte differentiation and metabolism, 
suggesting its potential as an anti-obesity therapy (Sanderson et al., 2014).  
 
Rooibos may possess additional hepatoprotective effects such as anti-cirrhotic effects reported 
in a carbon tetrachloride (CCl4)-rat model of fibrosis (Ulicna et al., 2003). Lee & Bae (2015) 
showed anti-mutagenic effects of isolated rooibos compounds (aspalathin and nothofagin) in 
response to lipopolysaccharide (LPS) induced liver injury. Alternatively, Monsees and 
Opuwari (2016) reported that a 5% unfermented rooibos extract significantly increased liver 
mass (related to an increase in hypertrophy) but maintained liver architecture (no fibrosis).  
 
In contrast to the above mentioned hepatoprotective affects, three case reports have reported 
hepatotoxic effects associated with rooibos consumption. All three are associated with 
excessive or recent introduction of rooibos into the diet thereafter liver related symptoms e.g. 
raised ALT and AST which lead to the diagnosis (Sinsalo et al., 2010; Engels et al., 2013; 
Zacharia & Whitlatch, 2013).Therefore, collectively the effects of rooibos on the liver can be 
protective however, the effects of chronic rooibos consumption should be monitored. 
 
2.6.4.3 Nephroprotective effects of rooibos 
To date, limited studies have studied the effect of both fermented and unfermented rooibos on 
the kidney and even fewer the histomorphometric effects. Nephrotoxicity, hepatotoxicity and 
oxidative stress caused by tert-butyl hydroperoxide were alleviated by rooibos supplementation 
in rats (Ajuwon et al., 2013). A 2% and 5% unfermented rooibos extract showed no effect on 
kidney mass in female rats on a control diet (Monsees & Opuwari, 2016) whereas in male rats 
a 5% unfermented and fermented rooibos extract respectively, significantly decreased kidney 
mass relative to body mass (Opuwari & Monsees, 2013). Monsees and Opuwari (2016) 
reported no histological changes in morphology or structure of the kidney after rooibos 
exposure however, an increase in creatinine, a marker of kidney function, was present in the 
fermented treatment group only. In contrast to Monsees and Opuwari, fermented rooibos 
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protected kidney function in male wistar rats (Ajuwon et al., 2016). A study by Pereira (2017) 
reported no significant changes in the renal corpuscle or proximal convoluted tubules in male 
wistar rats supplemented with a 2% fermented rooibos solution. Therefore, the effects of 
rooibos on the kidney are under reported and as kidney function is paramount to many 
metabolic disorders establishing the effects of rooibos on the kidney need to be clearly defined.  
 
2.7  RATIONALE AND MOTIVATION OF THE STUDY 
Afriplex GRT™ is a unfermented green rooibos laboratory standardized extract that may 
attenuate obesity related histomorphometric changes due to the polyphenols it contains. This 
extract contains 12% aspalathin, a polyphenol which has promising effects antidiabetic effects 
(Kawano et al., 2009; Muller et al., 2012; Son et al., 2013). Orientin and iso-orientin, 
metabolites of aspalathin, have shown possible antidiabetic effects as well (Sezik et al., 2015). 
Quercetin, another component of Afriplex GRT™ may have possible anti-obesity effects (Jung 
et al., 2013; Liu et al., 2015). As the synergistic effects of extracts are believed to make them 
superior to individual polyphenol compounds (Muller et al., 2017) this green rooibos extract 
may effectively reduce the effects of a HFD. 
 
A major concern in current research is the use of the term “HFD” which is not clearly defined, 
reported or delineated. In the literature anything from 30-60% calories from fat (Jang, 2017) 
can be defined as a HFD which has led to substantial variability in results reported (Buttener 
et al., 2006). As diet pairings used in animal studies (control and HFD) are essential for 
producing results which are meaningful, comparable, and can be replicated (Jang, 2017; 
Pellizon & Ricci, 2018) a few key factors should be considered. The type and source of fat 
(unsaturated versus polyunsaturated versus saturated), animal strain, phytoestrogen content, 
and the sugar source (Warden & Fisler, 2008). The sugar source used in animal models is 
extremely relevant to closely replicate the effcts produced from excesss sugar intake associated 
with an unhealthy western diet. 
 
Fructose is used commercially as an alternative sugar source to sucrose (Elliot et al., 2002). 
Sufficient evidence has determined that fructose aggravates body mass gain and may contribute 
to dyslipidaemia and insulin resistance (Warden & Fisler, 2008; Mathijs et al., 2014). Dietary 
consumption of fructose has also been associated with a decrease in plasma leptin and post-
meal insulin secretion as fructose does not activate pancreatic β-cells. Fructose is preferentially 
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metabolized to lipids in the liver (Elliot et al., 2002) where it directly and indirectly inhibits 
free fatty acid oxidation (Schultz et al., 2013). Daily fructose consumption is associated with 
increased hepatic fibrosis and inflammation (Schultz et al., 2013) and is associated with 
increased hepatic macrovesicular steatosis and triglycerides (Lee et al., 2015). In the liver, 
fructose suppresses glucose uptake, which results in increased blood glucose and increased 
insulin secretion which may be related to insulin resistance (Schultz et al., 2013). As fructose 
consumption has increased due to the use of fructose corn syrup commercially, a link to obesity 
and insulin resistance is suggested (Elliot et al., 2002). Therefore, the present study aimed to 
determine whether a green rooibos extract could effectively ameliorate the histomorphometric 
effects of a HFD in a rodent model. 
  




3 RESEARCH QUESTIONS, AIM AND 
OBJECTIVES 
CHAPTER THREE: 
RESEARCH QUESTIONS,  
AIM AND OBJECTIVES 
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3.1 RESEARCH QUESTION 
• Does Afriplex GRT™ have ameliorative histomorphometric effects in diet-induced 
obese rats and their age matched controls? 
• Can Afriplex GRT™ prevent morphological changes and or pathology in the pancreas, 
liver and kidney of obese rats? 
 
3.2 AIM 
To determine the histomorphometric effects of a HFD and a HFD in combination with Afriplex 
GRT™ on the pancreas, liver and kidney in male Wistar rats. 
 
3.3 OBJECTIVES 
I. Routine histomorphological examination of the pancreas, liver and kidney in four study 
groups namely three control groups control (C), green rooibos control (GRT), high-fat 
diet control (HFD) and a high-fat diet fed green rooibos supplemented (HFD-GRT) 
experimental group. 
II. Pancreas, to determine; 
a. Pancreatic islet size, number and volume per tissue reference area; 
b. α- and β-cell areas; 
c. Lipid infiltration with Oil red O; and 
d. Evaluate pathology on H&E stained tissue. 
III. Liver, to determine: 
a. Volume of steatosis; 
b. Area of steatosis; 
c. Evaluate pathology using the Non-Alcoholic Fatty Liver Disease (NAFLD) 
Activity Score (NAS); and 
d. Liver structural integrity by studying reticular fibres using Gordon and Sweet’s 
Reticulin impregnation technique. 
IV. Kidney, to determine 
a. Morphometric changes on the renal corpuscle, proximal convoluted tubules and 
arcuate arteries using periodic acid Schiff stain; and 
b. Evaluate pathology using H&E. 




H0  Afriplex GRT™ has no ameliorative effects on the histomorphometry of the pancreas, 
liver and kidney in diet-induced obese rats. 
 
H1  Afriplex GRT™ has ameliorative effects on the histomorphometry of the pancreas, 
liver and kidney in diet-induced obese rats. 
 
  




4 MATERIALS AND METHODS  
 
CHAPTER FOUR: 
MATERIALS AND METHODS   
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4.1 ETHICAL CLEARANCE 
Ethical approval was granted for the use of tissue in the present histomorphometric study (SU-
ACUD16-00139). The present study used tissue harvested from related studies that were 
ethically cleared. One study focused on vascular function and liver antioxidant capacity in this 
HFD-GRT model (SU-ACUD15-00102); (Maqeda, 2018) while another focused on 
myocardial insulin resistance and mitochondrial function (Kroukamp, 2018); (SU-ACUD 16-
00179). Both studies are unpublished masters theses from which the liver, pancreas and kidney 
samples used in the present study were harvested. The present study conformed to the key 
principles for humane animal research outlined by Stellenbosch University Research Ethics 
Committee: Animal Care and Use (REC: ACU). Animal care was guided by the “South African 
National Standards: The care and use of animals for scientific purposes” (SANS, 10386, 2008) 
as set out by the South African Bureau of Standards. Animals were monitored for stress, illness 
or injury daily to ensure their wellbeing.  
 
4.2 ANIMAL HOUSING AND STUDY GROUPS 
Male Wistar rats (N=28) of body mass 150 g to 210 g (eight weeks old) were randomly 
allocated into the following four groups: control (C), green rooibos (GRT) control, high-fat 
diet (HFD) control and HFD-GRT experimental group (Figure 4.1). Rats were housed in plastic 
cages, four animals per cage in the Central Animal unit, Faculty of Medicine and Health 
Science, Stellenbosch University. Animals were kept under a 12-hour light and 12-hour dark 
cycle, 40% humidity at room temperature (± 23 ˚C).  
 
4.3 ANIMAL FEEDING PROGRAMME 
Two feeding programs were used for a period of 16 weeks. The control (C) and GRT groups 
were fed rodent breeder feed (Labchef, Nutritionhub, South Africa), while the HFD and HFD-
GRT animals received a diet additionally containing fat, fructose and cholesterol. The 
composition of the main dietary components is shown in Table 4.1. 
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Table 4.1: A comparison of the control and high-fat diets treatments, contribution of each food 
group in the diets fed to the animals for the duration of the study. 
Food group  Control diet  High-fat diet  
Carbohydrate (%) 51.9 28.8 
Protein (%) 25 14.3 
Fat g/100 g 4.8 27.9 
Fructose g/100 g - 11 
Sucrose g/100 g 6.6 13.3 
Cholesterol - 6.4 
Kilojoules/100 g 1272 1829 
Kilocalories 304.02 437.14  
 
4.4 PREPARATION OF FEEDS AND SUPPLEMENTATION 
4.4.1 High-fat diet preparation according to Huisamen et al., 2013 
The HFD was prepared by soaking rodent breeder feed pellets (390 g) (Labchef, Nutritionhub, 
South Africa) in a large bowl with boiling water (200 ml) until soft. The additional ingredients 
were added, which included cholesterol (10 g), fructose (100 g), Holsum™ cooking fat (750 
g), Nestle™ sweetened condensed milk (790 g) and casein (100 g). This combination was 
mixed forming a homogenous product. The mixture was rolled into balls approximately 50 g 
in weight and refrigerated at -4 º C. One ball was placed into each cage daily.  
 
4.4.2 Afriplex GRT™ supplementation 
Animals from the GRT and HFD-GRT groups were supplemented with the Afriplex GRT™ 
extract, an unfermented Aspalathus linearis extract high in aspalathin. The extract and its 
polyphenolic composition were supplied by the South African Medical Research Council (SA-
MRC) (Addendum D). The extract was fed to the animals in the form of jelly blocks since rats 
have been shown to like sweet tasting foods (Chellan et al., 2008). The animals received a 
dosage of 60 milligrams per kilogram body mass of the animal per day. This ensured that each 
animal received a dosage according to their body mass (Addendum D). From week 11 to 16 
the GRT and HFD-GRT animals were given one GRT supplemented jelly block, while the 
control and HFD animals received placebo jelly blocks. To ensure absolute compliance and 
dose control, a single block of jelly was given daily by hand. This helped to control that all 
animals received jelly to normalize the dietary sugar content (refer to Figure 4.1).  
 
Jelly blocks were prepared by dissolving 4 g of Moir’s™ strawberry jelly and gelatine 
respectively, in 25 ml of boiling water. The mixture was cooled, followed by the addition of 
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the Afriplex GRT™ extract powder, at the calculated dosage according to the body mass was 
added. The mixture was placed on a magnetic stirrer to ensure the jelly and gelatine granules 
dissolved. A repetitive pipette (Gilson™ Distriman™ Positive displacement repetitive pipette) 
was used to transfer 1 ml of the mixture into an ice-block container. The jelly was made weekly 
and kept in sealed containers protected from light and precipitation in a freezer (-4 ºC). 
 
 
Figure 4.1: Summary of animal lifespan, dietary and Afriplex GRT™ supplementation. Twenty-
eight male Wistar rats were allocated to the four study groups; control (C), high-fat diet (HFD), control 
diet and Afriplex GRT™ supplemented (GRT) and high-fat diet fed and Afriplex GRT™ supplemented 
(HFD-GRT).  
 
The dosage of Afriplex GRT™ was deduced by reviewing the literature, as no previous study 
used this exact extract (Muller et al., 2012; Kamakura et al., 2015). Muller and colleagues used 
an aspalathin-rich green rooibos extract where a 25mg/kg dosage showed a glucose lowering 
effect while a 30mg/kg extract was more effective at reducing oral glucose tolerance compared 
to vildagliptin (a dipeptidyl peptidase 4-inhibitor) an antidiabetic drug. Previously, Kamakura 
et al. 2015 similarly showed a decrease in fasting blood glucose with a green rooibos extract 
(same as Muller et al., 2012) in KK-Ay mice, a dosage calculated to be about 250mg/kg/day. 
Further consultation revealed that primates receive a dosage of 90mg/kg/day which relates to 
180mg/kg/day in rats. Therefore, the dosage of 60mg/kg/day was determined as a mid-point 
between Muller et al., 2012 and the dosage received by primates (Kroukamp, 2018). 
 
4.5 ANIMAL ANAESTHESIA AND TISSUE HARVESTING 
At the end of the study period (16-weeks), animals were weighed using an electronic scale. An 
overdose of sodium pentobarbital (Euthanze©, Bayer, South Africa) was administered to each 
animal (160 milligrams per kilogram body mass, intra-peritoneally) by a researcher authorised 
by the South African Veterinary Council. Once corneal, pedal and withdrawal reflex were 
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absent, the thoracic cavity was opened, and the heart removed (death by exsanguination). The 
pancreas, liver and right kidney were removed, weighed and fixed as detailed in Addendum C.  
 
4.6 HISTOLOGY 
4.6.1 Tissue preparation 
Tissues allocated for standard histological processing were stored in 10% neutral buffered 
formalin (NBF) for a period of 36 to 48 hours. Thereafter, organs were placed into labelled 
plastic embedding cassettes. The tissues were processed in the Shannon Eliot Duplex™ tissue 
processer (OptoLaboratory, South Africa) on a 17-hour cycle according to the protocol in 
Addendum F. Processed tissue was embedded in paraffin wax using the Leica™ EG 116 
embedder (SMM instruments, Germany). Blocks were cooled on a cold plate for an hour and 
kept in the refrigerator for 15 minutes prior to sectioning. Tissues were sectioned using the 
Lecia™ RM 2125 rotary microtome (SMM instruments, Germany). Sections were transferred 
to a water bath heated to 34 to 37 ºC and placed on standard microscope slides for standard 
stains or positively charged microscope slides for immunohistochemistry and Oil red O. Slides 
were placed in the oven to remove wax. After the sections were stained, a cover slip was 
mounted using distyrene, a plasticizer, and xylene (DPX) mounting media.  
 
The frozen pancreas and liver tissue were removed from storage and kept in liquid nitrogen (-
196 ºC). A portion of the pancreas and liver (approximately 10 mm2) was placed on the tissue 
mount, covered with tissue freezing media (SHH0026, Merck, North America) and set by 
submersion in liquid nitrogen. The Leica™ CM1850 UV cryostat microtome (SMM 
instruments, Germany) was used to section the tissue. Sections were placed on positively 
charged microscope slides and kept in the freezer prior to staining. After staining, slides were 
left to air dry and aqueous mounting media (G 0918, Merck, Pty, Ltd) was used to mount the 
coverslip and stabilized with clear nail varnish. 
 
4.6.2 Tissue staining 
Haematoxylin and Eosin stain  
To study morphology and diagnose pathology in the pancreas, liver and kidney, the 
haematoxylin and eosin (H&E) stain was used. Haematoxylin stains the nuclei blue (affinity 
for acidic structures) and eosin stains the remainder of the tissue pink to red (affinity for basic 
structures); (Bancroft & Gamble., 2008). The Leica™ Auto-Stainer XL (SMM instruments, 
Germany) was used to stain 5 µm sections of the pancreas, liver and kidney (Addendum G). 
Stellenbosch University  https://scholar.sun.ac.za
41 
 
The H&E stain was used for histopathological analysis, to determine if special stains were 
necessary and for histomorphometry.  
 
4.6.3 Pancreas 
Double antibody labelling of pancreatic islets 
Formalin fixed pancreata were sectioned at 4 μm at three levels, with the three levels 20 and 
30 μm apart (serial sections). A manual double antibody staining approach, using anti-glucagon 
and subsequently anti-insulin antibodies, was used. The tissue was labelled according to the 
standard operating procedure of the SA-MRC, ICC\B7-V01(Addendum H). 
 
The sections were dewaxed in an oven at 60 ºC for 30 minutes and dehydrated to water. To 
block for endogenous peroxidases, a 3% hydrogen peroxide (H2O2) was prepared in a staining 
jar, and the slides were placed in the solution for five minutes. To ensure contrast and 
heightened antibody signal, thorough washing of slides with 0.05 M Tris Buffered Saline (TBS) 
pH 7.2 was performed between steps. After washing, the area around the sections were dried 
and traced with a Dako™ pen to ensure even coverage of the small quantities of antibody 
solution(s).  
 
Thereafter, the pancreata were incubated in a moisture chamber for 20 minutes with a 1:20 
dilution of normal goat serum to block for non-specific background staining. The primary 
antibody, 100 µl polyclonal anti-glucagon (1:50) (A0564, Dako, North America, Inc) was 
applied to the slides in a moisture chamber at room temperature (±25 ºC) for 30 minutes. The 
washing step was repeated, the area around the sections were dried, and the tissue was 
incubated with biotinylated rabbit anti-IgG in a moisture chamber for a further 30 minutes. The 
slides were washed once more, after which they were incubated with Vectastain® Avidin biotin 
(PK6100, Vector laboratories,) complex in a moisture chamber for one-hour to detect biotin 
molecules. After washing, the area around the section was dried with tissue paper and liquid 
3’3-diaminobenzidine (DAB) (K5355. Dako, North America, Inc) as well as substrate 
chromogen solution were added to slides for five minutes. During the DAB staining, the 
progress was viewed under a standard light microscope to prevent overstaining. The slides were 
washed with distilled water followed by a 0.05 M TBS washing step to conclude anti-glucagon 
labelling.  
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The second labelling procedure using anti insulin was applied to the slides whereby the area 
around the section was dried and slides placed in a moisture chamber. To block non-specific 
binding, a 1:20 dilution of normal horse serum was added, and the slides were incubated for 
20 minutes at room temperature. Subsequently, a 1:5000 dilution using monoclonal anti-insulin 
antibody (K5355. Dako, North America, Inc) was added, and the slides were incubated 
overnight (20-24 hours) in a refrigerator at 4 ºC. Following incubation, the slides were brought 
to room temperature and the EnvisionTM G/2 double stain system rabbit/mouse kit (K5361. 
Dako, North America, Inc) was used according to manufacturer’s instructions to complete the 
anti-insulin antibody labelling.  
 
This staining procedure labelled insulin secreting β-cells red-pink and glucagon secreting α-
cells brown. Internal positive, external and method controls were included to validate the stains 
and the staining procedure. Control pancreas tissue from the C-group of the present study was 
used as an internal positive control, kidney tissue from an unrelated study was used as a method 
control and pancreas tissue from an unrelated study as an external control. 
 
4.6.4 Pancreas and Liver 
The following stains were done on both the pancreas and liver tissue to determine the presence 
of lipid infiltration.  
 
Oil red O stain  
Oil red O stains triglycerides, fatty acids and lipoproteins (Mehelm et al., 2013). Frozen 
pancreas and liver tissue were prepared as detailed in section 4.6.1. The cryostat was used to 
produce serial sections of the pancreas (n=3) and liver (n=5) at 8 µm and 10-12 µm respectively 
on positively charged microscope slides. The internal microtome environment was maintained 
at -15 ºC and -12 ºC, respectively. Tissue was stained within 24-hours of sectioning, and 
imaged immediately after staining 
 
Slides were incubated in an Oil red O-dextrin solution (01391, Merck, North America) and 
counterstained with a 50% Crystal violet solution (V5265,Merck, North America) to create 
contrast and visualize cellular anatomy (Bancroft & Gamble, 2008); (detailed in Addendum I). 
Intraperitoneal fat attached to muscle was used as an external positive control and the pancreas 
and liver tissue of the C-group as the internal control.  
 




4.6.5.1 Masson’s trichrome 
Masson’s trichrome staining technique is a specialized stain which stains collagen type-1 fibres 
blue-green (light green solution), nuclei black-purple (haematoxylin) and the tissue 
parenchyma red-orange (Fuchsin Ponceau Orange G working solution) (Bancroft & Gamble, 
2008; Saxena, 2010). This stain was used to detect fibrotic changes in the liver. Tissues were 
sectioned at 5 µm and placed on standard microscope slides for a manual protocol (Addendum 
J). Human skin was used as an external control and liver tissue from the C-group as an internal 
control.  
 
4.6.5.2 Gordon and Sweet’s silver impregnation technique (Reticulin stain)  
The reticulin technique is based on the nature of reticulin fibres to be argyrophilic and was used 
to demonstrate the supportive reticulin network in the liver by impregnating fibres black 
(Saxena, 2010). Disruption of this network may result in reticulin fibres collapsing or forming 
thickened plates (Singhi et al., 2012). Formalin fixed liver tissue was sectioned at 5 µm and 
stained according to Addendum K (Bancroft & Gamble, 2008). The C-group acted as an 
internal control, and human skin was used as an external positive control.  
 
4.6.6 Kidney  
4.6.5.3 Periodic acid Schiff stain 
Periodic acid Schiff (PAS) is used routinely to determine alterations in the basement membrane 
of the renal corpuscle and tubules of the kidney. Periodic acid oxidizes the hydroxyl (-OH) 
group of glycogen, glycoproteins, glycolipids and mucins. The exposed aldehyde groups react 
with the chromophores in Schiff’s reagent to produce a bright purple-magenta colour (Saxena, 
2010). Tissue was sectioned at 5 µm, placed on standard microscope slides and stained using 
a manual protocol detailed in Addendum L. External positive and internal controls were run 
simultaneously with the staining of the study tissue, namely, rat colon and control tissue from 
the control study group.  
 
4.7 MORPHOMETRIC TECHNIQUES  
Morphometry is the measure of form and is frequently used in histopathology to describe 
measurements made from two-dimensional tissue sections (Zaitoun et al., 2001). A summary 
of the morphometric techniques used per organ is illustrated in figure 4.2. Composite images 
of the entire tissue sections on each slide of the pancreas and kidney were taken using the Nikon 
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software and camera (Table 4.2). Images of the liver were taken using the Zeiss software and 
camera (Table 4.2) detailed in the liver morphometry section. Histomorphometric analysis was 
completed using ImageJ (https://imagej.net/ImageJ), STEPanizer © Stereology Tool, and Zen 
Lite™ 2012 software packages. Each software package was calibrated using the scale bar 
indicated on the images.  
 
Figure 4.2: A summary of the morphometric measurements performed on the various 
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Proximal convoluted 
tubules
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Table 4.2: The microscope systems used for scanning, production of micrographs and analysis of 
the pancreas, liver and kidney. 
 Nikon system Carl Zeiss system 
Equipment Nikon Eclipse Ti-S microscope 
(Nikon instruments Inc., 
Copyright 1991-2015) 
- PRIOR ProScan III, 
Nikon automated tissue 
scanning software 
- Nikon NIS Imaging 
Software version 4.40 
- Nikon Digital Sight DS-
Fic, Nikon corporation, 
Japan attached camera 
Zeiss Axioskop 2 light 
microscope (801452) (Carl 
Zeiss, AG, Oberkochen, 
Germany) 
- Axiovision version 
4.7.2.0 software 
- Zen (2012) blue 
edition Version 1.1.2.0 
- Axiocam 105 
(Camera) 
Tissue Pancreas and kidney Liver 
4.7.1 Morphometry of the pancreas 
Morphometric analysis of the pancreatic islets, α- and β-cells surface areas was performed on 
the double antibody labelled sections using methods adapted from Ricculio et al. (2004). Each 
section was scanned at 100x magnification with a 15% overlap per image. The individual 
images were stitched to form a composite image of the full tissue section to determine section 
area as a reference point. Furthermore, individual images of the pancreatic islets were used for 
morphometric analysis. 
 
A basic macro was designed which converted the composite image to a red/green/blue (RGB) 
stack greyscale image (Addendum M). The tissue section was manually traced, and the tissue 
selected using the threshold function. ImageJ then automatically determined the section area in 
µm2. The section area in µm2 was converted to mm2 (Figure 4.3). 
  




Figure 4.3: Determination of tissue section area in µm2 as a reference point. (A) Each pancreas was 
double antibody labelled with anti-glucagon and anti-insulin antibodies and scanned using the Nikon 
microscope and automated scanning software. (B) Composite images of the entire section area were 
converted to a red/green/blue stack (greyscale images). (C) The tissue section was manually traced 
(yellow) excluding blood vessels, peripancreatic fat and lymphoid tissue. The tissue section was 
selected using the threshold bar (red) and the section area (µm2) determined by ImageJ. Bar represents 
1000 µm. 
 
Immunohistochemistry was used to differentiate the glucagon and insulin secreting hormone 
cells in the pancreatic islets. The area of the islets, α- and β-cells as well as the percentage of 
α- and β-cells positive areas were determined in µm2. The individual images of the pancreatic 
islets were evaluated and any images in which the full islet was absent, were excluded. The 
islet circumference was traced to determine total islet surface area (Figure 4.4). The image was 
converted to an RGB stack, the red filter was selected and the α- and β-cell positive areas were 
measured individually. The threshold was adjusted for each image to account for changes in 
staining intensity.  
 




Figure 4.4: Morphometric measurements on the pancreatic islets, α- and β-cells (µm2). (A) A 
representative pancreatic islet double antibody labelled with anti-glucagon (brown) and anti-insulin 
(pink/red). (B) The perimeter of the pancreatic islets was manually traced (yellow). (C) the α- cell area 
was selected (green) using the threshold bar and area determined (µm2). (D) The β-cell area was 
determined by selecting the pink (blue) stained region within the perimeter of each islet (µm2). Bar 
represents 20 µm. 
 
A total of 400 islets in each experimental group were compared. For each animal all the islets 
analysed were organized into a data sheet in Microsoft Excel. Any islets which did not show 
both α- and β-cells were excluded. The remaining islets were then numbered and using a 
random number generator, islets were selected based on the number allocated to them. The 
selected islets were organized into a separate data sheet and means calculated so that statistical 
analysis could take place.  
 
Islet volume was determined by applying a 1000 µm2 grid to the composite image (Figure 4.5) 
and determining the number of points touching islets (P(Islets)) versus the points touching the 
reference area (pancreatic exocrine tissue, P (Reference area)) (Equation 4.1). The three levels of 
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tissue (20 and 30 µm apart, section 4.6.3.1) were scanned using the Nikon system and a 1000 
µm2 grid was superimposed over the composite images using ImageJ. The average islet volume 
per group was determined. This grid size was used to determine the number of islets per 1000 
µm2 to standardize islet number per (1000 µm2) section area. 
 
𝑉𝑣 = 𝑃(𝐼𝑠𝑙𝑒𝑡) − 𝑃(𝑅𝑒𝑓𝑒𝑟𝑒𝑛𝑐𝑒 𝑎𝑟𝑒𝑎) 
Equation 4.1: The volume of pancreatic islets per total pancreatic section area. 
 
 
Figure 4.5: Determination of pancreatic islet volume using ImageJ. A 1000 µm2 grid was 
superimposed over the composite image (A) and the points touching islets divided by the total number 
points on the tissue was used to determine islet volume (B). 
 
4.7.2 Morphometry of the Liver 
For morphometry, 12 images of both the H&E (200X) and Oil red O stained liver tissue (100X) 
per animal were captured using the Zeiss system by a blinded observer (Figure 4.6). The images 
were used to quantify the volume of steatosis using a 36-point grid and area of steatosis by 
image processing according to methods described by Catta-Pretta et al. (2011).  
 
A B 
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Figure 4.6: Method of image capture. On the left schematic representation of a standard microscope 
slide with a section of liver tissue (A) (pink). The tissue was divided, into four equal parts on the slide, 
approximately 4 mm apart using a permanent maker. Three images per part were captured on the H&E 
(200X) and the Oil red O stained liver tissue (100X). Images were captured systematically in the 
direction of the arrow (black). An example of a micrograph of control liver tissue stained with H&E is 
seen on the right (B). 
 
To assess the volume of steatosis, a ratio of points touching lipid vacuoles (Pp) compared to 
the total number of test points (PT) was determined (Equation 4.2). A 36-point grid was applied 
to ten randomly selected H&E and Oil red O micrographs using the STEPanizer © software. 
A guard area (10 µm2), to ensure that only hepatocytes shown completely was applied per 
image. The image was studied from left to right and points touching the white unstained area 
where lipid deposits were located prior to alcohol processing were counted. The count was 
collected for all images per animal and transferred to an Excel spreadsheet where Equation 4.2 
was applied to determine the volume of steatosis (Figure 4.7).  
 




Equation 4.2: Volume of steatosis was determined by dividing the number of points touching lipid 
vacuoles by the total number of points in the grid (36). 
 
A B 




Figure 4.7: Determination of the volume of steatosis. The 36-point grid and guard area (red box) 
produced using the STEPanizer © software to determine the volume of steatosis in control livers (A) 
and fatty livers (B). Images were analysed from left to right following the blue arrow illustrated on 
figure A. Green circles referred to the subsampling area. 
 
To determine the area (µm2)of lipid deposits, ten images of H&E and Oil red O stained liver 
tissue from each study group were randomly selected (Figure 4.8 A-H). Each individual image 
(Figure 4.8 A & E) was converted to a greyscale RGB image (Figure 4.8 B & F) where a 
threshold was applied to assist selection of the unstained white areas in the micrograph. 
Subsequently, that image was converted to a black and white binary image (Figure 4.8 C & G) 
and the hepatic tissue area was determined. The binary image was inverted (Figure 4.8 D & H) 
to determine area of steatosis. In the control and GRT groups, the white area in the binary 
image (C) represented the sinusoids and the black area the hepatic tissue. Whereas, in the HFD 
fed groups the white area represented lipid infiltration and the black area the hepatic tissue. 
  
A B 




Figure 4.8: Illustration of image transformation to determine the area of hepatic tissue and 
steatosis in haematoxylin and eosin (A-D) and Oil red O stained tissue (E-H). Individual images (A 
& E) were first transformed to RGB stacks (B & F) and then converted to binary images (C & G) to 
measure the tissue area. The binary images were inverted (D & H) to allow the sinusoid area to be 
measured in control fed animals. In contrast in the HFD fed animals, sinusoids were obscured due to 
extensive hepatocyte swelling. Thus, the inverted binary images measured steatosis. Bar represents 10 
µm. 
 
4.7.3 Morphometry of the Kidney  
Morphometric analysis of the kidney was performed on the glomeruli, Bowman’s capsule, 
proximal convoluted tubules (PCT), and arcuate arteries. The full tissue sections of the PAS 
stained kidney were scanned at 200X using the Nikon software and camera (Table 4.2). 
Individual images were captured with a 15% overlap and stitched to form a composite image.  
 
The circumference of the glomerulus, Bowman’s capsule, inner and outer perimeter of the 
PCT’s were traced (Figure 4.9 A & B). Area, diameter, and radius of the various structures 
were derived by the Zen lite™ 2012 software. The renal space was determined by subtracting 
the glomerular area from the Bowman’s capsule area. To determine the PCT wall area, the 
difference between the outer surface area and inner surface area was determined. Similarly, the 
PCT wall diameter was determined by subtracting the outer surface diameter from the inner 
surface diameter. 
 




Figure 4.9: Morphometric measurements of the renal corpuscle (Bowman’s capsule and 
glomerulus) and proximal convoluted tubules. (A) The glomerulus and Bowman’s capsule 
perimeters were traced, and the area, diameter and radii determined in µm2. (B) Three closely related 
proximal convoluted tubules per glomerulus, inner and outer perimeter were traced to determine the 
area, diameter and radii determined in µm2. Bar represents 20 µm.  
 
Additionally, the renal arcuate arteries were analysed using methods adapted from Reddi et al. 
(2001). The circumference of the artery and arterial lumen were traced to determine the outer 
and luminal areas of the arterial wall. The internal diameter of the artery was measured using 
two perpendicular lines which crossed the lumen of the artery. The internal diameter was 
described as the shortest (IDshort) and longest (IDLong) distance from one adluminal side of the 
internal elastic lamina to another crossing the arterial lumen. (Figure 4.10). Equations 4.3, 4.4, 
4.5 and 4.6 used to calculate the outer surface area, externa diameter, tunica media thickness 
and tunica media to lumen ratio. 
Figure 4.10: Schematic diagram describing the measurements completed on the arcuate arteries. 
The outer and luminal surface area (red thin and bold circles respectively) as well as the internal 
diameter short (beige) and long (blue) were determined using the Zen (2012) software. Modified from 
the description by Reddi et al. (2001). 
 
OSA:  Outer surface area 
LSA: Luminal surface area 
IDLong:  Longest internal diameter 
IDShort:  Shortest internal diameter 
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Equation 4.3: Outer surface area of the arcuate artery Reddi et al. (2001). 
 














Equation 4.5: Tunica media thickness Reddi et al. (2001). 
 






Equation 4.6: Tunica media to lumen ratio of the arcuate artery Reddi et al. (2001). 
 
4.8 HISTOPATHOLOGY EVALUATION OF THE PANCREAS LIVER AND 
KIDNEY 
A veterinary histopathologist (Dr. Rick Last, VetDiagnostix) was consulted to confirm the 
pathology in the pancreas, liver and kidney. The pathologist was blinded to the treatment 
groups to ensure an unbiased assessment of the tissue was conducted. Table 4.3 describes the 
pathology evaluated by the veterinary histopathologist  
 
Table 4.3 Pathology evaluated by the veterinary histopathologist of the pancreas, liver 
and kidney. 









Vacuolar degeneration Oedema 
Oedema Hepatocyte swelling Proteinaceous casts 
Congestion  Haematopoiesis  Congestion  
 mononuclear cell infiltration  
 sinusoidal dilation  
 Kupffer cell proliferation  
 Central vein duplication & 
dilation 
 
 Capillary canal formation  
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The non-alcoholic fatty liver disease (NAFLD) Activity Score (NAS) was used to grade and 
score the liver (Kleiner et al., 2005). This is an accredited system used to assess steatosis, 
fibrosis, inflammation, hepatocyte changes and provide a diagnostic tissue score. 
Haematoxylin and eosin sections were used for standard evaluation and Masson’s trichrome to 
assist the evaluation of liver fibrosis.  
 
Five scorers evaluated the entire tissue section per animal using the NAS score. To ensure each 
scorer scored animals from each of the four study groups the animals were randomly selected 
based on tissue block numbers. The block numbers were put in a random order, every second 
number selected and placed into five diverse groups for analysis. Each observer was provided 
with a grading sheet to accustom themselves with the scoring system one day prior to analysis. 
Using the grading sheet, each scorer assigned a score for steatosis, fibrosis, inflammation. and 
hepatocyte injury in the liver tissue (Table 4.4). These scores were used for inter- and intra-
observer scores. In addition, the scores were compared to the evaluation given by a veterinary 
histopathologist. Once analysis was complete, data was organized according to the four study 
groups and means determined for statistical analysis. 
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Table 4.4: The non-alcoholic fatty liver disease activity score used to evaluate the liver tissue 
Adapted from Kleiner et al., 2005. 
Category Detailed explanation per subcategory Score 
Steatosis    
Grade 5% 0 





Location   
  Zone 3 0 
Zone 1 1 
Azonal 2 
Panacinar 3 
Microvesicular steatosis   
Contiguous pattern Not present 0 
Present 1 
Fibrosis stage   
Predominant distribution pattern None 0 
Perisinusoidal or periportal 1 
Mild, zone 3 perisinusoidal 1A 
moderate zone 3 perisinusoidal 1B 
portal/periportal 1C 
Perisinusoidal and portal/ periportal 2 
Bridging fibrosis 3 
Cirrhosis 4 
Inflammation   
Lobular inflammation No foci 0 
  <2 foci per 200x field 1 
2-4 foci per 200x field 2 
>4 foci per 200x field 3 
Microgranulomas   
(Macrophage aggregates) absent 0 
present 1 
Large lipogranulomas   
in portal areas or adjacent to central vein Absent 0 
present 1 
Portal inflammation   
in portal areas or adjacent to central vein none to minimal 0 
greater than minimal 1 
Liver cell injury   
Ballooning None to rare 0 
  Few balloon cells 1 
  many cells/prominent ballooning 2 
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4.9 STATISTICAL ANALYSIS 
Professor Martin Kidd from the Centre for Statistical Consultation, Department of Statistics 
and Actuarial Sciences at Stellenbosch University was consulted for statistical analysis. The 
data was organised in Microsoft Excel spreadsheets blinded according to tissue block number 
and then organized by study group post analysis. Statistical analysis was performed using the 
Statistica® version 13.2 software (Dell, 2014, United States of America).  
 
The normality of the data was determined by plotting the values on a theoretical line graph to 
identify outliers. The slope of the line graph determined whether parametric or non-parametric 
tests were done. The data was represented as log10 transformations to improve the spread. Data 
in the present study was parametric. 
 
Descriptive statistics were performed including: mean values, standard deviations, and 
standard errors calculated with a 95% confidence interval. The mean values were plotted on 
graphs. One- and two-way analysis of variance (ANOVA) tests were conducted between 
groups and treatments (diet and Afriplex GRT™, respectively). This test assumes that all 
means are equal (null hypothesis) and tests the variations between the groups. Statistical 
significance was confirmed when the null hypothesis was rejected with a p-value of less than 
0.05 (p ≤ .05). To determine the uniformity of variance, a Levene’s test was performed by 
assuming all variances were equal. In contrast, when all variances were not assumed to be equal 
a Games Howell or weighted-means test was performed. 
 
Lastly, to determine whether any trends were present a Fisher Least Significant Difference 
(LSD) post-hoc test was performed. The Fisher test indicates trends between variables at 
LSD < .05. Statistical analysis of the histopathology was conducted using two-way tables and 
Chi square tests.  
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The following section will provide graphical, descriptive and statistical evidence, on 
histomorphometrically measurable effects of Afriplex GRT™ and a HFD on the pancreas, liver 
and kidney in male Wistar rats studied for 16-weeks. Two-way ANOVA tests were used to 
compare the control diet (C- and GRT) and the HFD diet (HFD and HFD-GRT) fed groups. 
This helped to determine whether the dietary treatment had a significant effect on the 
morphometric parameters. In addition, two-way ANOVA tests were performed to compare 
Afriplex GRT™ treated (GRT and HFD-GRT) and untreated (C- and HFD) groups. This was 
performed to determine whether Afriplex GRT™ had any ameliorative effects on the 
histomorphometry of the pancreas liver and kidney.  
 
5.1 THE EFFECT OF TREATMENT ON BODY MASS (BM) AND ORGAN MASS 
The Afriplex GRT™ treated (GRT and HFD-GRT) groups had a significantly lower BM 
compared to the untreated (C- and HFD) groups (p < .01). Additionally, The HFD-GRT group 
showed lower BM than the HFD group (LSD =.021) with a mean decrease of 55 g (Figure 5.1 
A) (Addendum O). 
 
Pancreas mass expressed as a percentage of body mass (Figure 5.2 B) was significantly lower 
in the Afriplex GRT™ treated (GRT and HFD-GRT) groups in comparison to the untreated 
(C- and HFD) groups (p = .045). Furthermore, significantly lower pancreas mass was observed 
between the C and the HFD-GRT group (p = .034); (Addendum O).  
 
Liver mass expressed as a percentage of body mass was significantly lighter in the Afriplex 
GRT™ treated (GRT and HFD-GRT) groups compared to the untreated (C- and HFD) groups 
(p = .033). Liver mass was significantly heavier in the HFD fed animals (HFD and HFD-GRT 
groups) compared to the control fed animals (C- and GRT groups); (p = .033). All study groups 
showed significant differences (all p < .001) (Figure 5.1 C); (Addendum O). 
 
Kidney mass expressed as a percentage of body mass was significantly lower in the HFD fed 
animals (HFD and HFD-GRT groups) compared to the control fed animals (C- and GRT 
groups); (p = .032). The HFD and HFD-GRT groups had significantly lower kidney mass in 
comparison to the C-group (p = .041 and p = .01 respectively); (Figure 5.1 D); (Addendum O). 
  




Figure 5.1: Final body mass and organ mass relative to body mass of the four study groups. 
Pancreas mass was expressed as a logarithmic transformation to make the data statistically normal. 
Significantly increased body and liver mass was observed in the HFD groups. A significant decrease in 
body and all three organ masses was seen in the HFD-GRT group. (C) control diet, (HFD) high-fat diet, 
(GRT) Afriplex GRT™ extract, (+) treated, (-) untreated. n=7 per group. Vertical bars denote 0.95 
confidence intervals.  
 
5.2 THE EFFECTS OF TREATMENT ON THE PANCREAS 
Micrographs of the pancreatic islets using three staining techniques are shown in Figure 5.2. 
Pancreatic islets in the present study, were morphologically normal containing majority β-cells 
located centrally with a mantle of α-cells on the periphery. The exocrine portion of the 
pancreas, acini similarly showed normal morphology with centroacinar cells with lightly 
stained lumens and darker stained apical regions containing zymogen granules. 




Figure 5.2: Histology of the pancreatic islets using three different techniques. Top row: H&E, Middle row: double antibody labelling with anti-glucagon 
(brown) and anti-insulin (pink) immunohistochemistry (IHC) and Bottom row: Oil red O. demonstrating lipids (red) in the HFD group, very little fat was 
observed in the HFD groups. H&E 400x magnification, IHC 200x magnification, Oil red O 100x magnification. (GRT) Afriplex GRTTM, (HFD) High-fat diet, 
and (HFD-GRT) High-fat diet Afriplex GRTTM animals. Bar represents 500 µm. (BV) blood vessel, (i) pancreatic islet, (*) lipid droplets, (d) intercalated duct. 
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5.2.1 The effects of treatment on Pancreatic islets 
The number, size and islets per reference tissue area were determined to investigate the effects 
of treatment on the pancreatic islets. Using absolute values, the total number of islets per study 
group was: C: 781, HFD: 609, GRT: 754 and HFD-GRT: 808. The size and number of islets 
per tissue reference area, was not significantly different across groups (Table 5.1). The mean 
islet size of 400 islets for each experimental group was significantly lower in the HFD fed 
animals (HFD and HFD-GRT groups) compared to the control fed animals (C- and GRT 
groups); (p = .011). Furthermore, the C- (p = .076), GRT (p = .046) and HFD (p = .053) groups 
had significantly larger islets than the HFD-GRT group (Figure 5.3). 
 
Table 5.1: Pancreatic islets expressed per reference tissue area. No significant differences were 
observed across groups. Data is expressed as mean ± standard error of the mean (SEM). 
 
C GRT HFD HFD-GRT 
Islets area (μm2) per tissue 
section area (μm2) (%) 
0.019±0.004 0.053±0.028 0.038±0.013 0.024±0.004 
Islet number per tissue 
section area in mm2 
0.85±0.11 1.29±0.18 1.40±0.11 1.91±0.75 
(C) control animals, (GRT), Afriplex GRT™ animals, (HFD) High-fat diet animals and (HFD-GRT) High-
fat diet Afriplex GRT™ animals. 
 
Figure 5.3: Pancreatic islet size. Mean islet area (μm2).Islet area was significantly reduced in the HFD-
GRT group in comparison to the C-group. (C) control diet, (HFD) high-fat diet, (GRT) Afriplex GRT™ 
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The volume of islets per 1000 μm2 of pancreatic tissue was not significantly different in dietary 
and Afriplex GRT™ treatments or across the study groups. (Figure 5.4 A & B). Level two had 
significantly more islets than level one and three. The HFD group (level two) had significantly 
more islets than the other study groups (across levels) (Figure 5.4 B).  
 
 
Figure 5.4: Pancreatic islet volume. Islet volume did not differ significantly across groups. 
Significantly more islets were present in the HFD group level 2 in comparison to many of the other 
groups however this could be related to the amount of tissue area. “Levels “ refer to tissue section one, 
two and three (Section 4.6.3). (C) control diet, (HFD) high-fat diet, (GRT) Afriplex GRT™ extract, (+) 
treated, (-) untreated. n=7 per group. Vertical bars denote 0.95 confidence intervals. 
 
5.2.2 Pancreatic islet α-cells and β-cell area 
The α-cells were not significantly different across the four experimental study groups. The 
percentage of α- and β-cells did not differ across groups either. When α- and β-cells areas were 
expressed as a percentage of islet area no significant differences were observed. Lastly, α-cells 
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Table 5.2: Pancreatic islet α- and β-cells areas. No significant differences were found when 
comparing groups or treatments. Data is expressed as mean ± standard error of the mean (SEM). 
 Area (μm2) C GRT HFD HFD-GRT 
 α-cells  1031.28±140.87 877.39±222.68 1102.43±142.87 648.44±107.39 
Percentage of α-
cells  
12.83±1.21 12.84±1.22 13.52±1.46 15.69±1.55 
Percentage of β-cells  72.91±3.82 69.72±2.34 74.81±1.51 69.47±3.72 
Percentage of α-
cells per islet area  
8.58±0.67 8.59±1.32 8.23±1.22 9.22±1.05 
Percentage of β-cells 
per islet area  
52.83±3.07 49.87±3.05 52.64±2.35 46.23±4.00 
Percentage of α-
cells per β-cells  
16.43±1.51 17.19±3.09 17.21±3.13 20.53±2.46 
(C) control animals, (GRT), Afriplex GRT™ treated animals, (HFD) High-fat diet fed animals and 
(HFD-GRT) High-fat diet Afriplex GRT™ treated animals.  
 
Pancreatic β-cells area (μm2) was significantly decreased in the HFD-GRT group in 
comparison to the C- (p = .008) and GRT groups (p = .009); (Figure 5.5). In addition, the area 
of β-cells was significantly reduced in the HFD fed groups (HFD and HFD-GRT) compared to 

































Figure 5.4: Pancreatic islets β-cells area of 400 Islets per group. β-cells area was significantly 
decreased in the HFD-GRT in comparison to the C- and GRT groups. (C) control diet, (HFD) high-fat 
diet, (GRT) Afriplex GRT™ extract, (+) treated, (-) untreated. n=7 per group. Vertical bars denote 0.95 
confidence intervals. 
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5.3 THE EFFECT OF TREATMENT ON THE MORPHOMETRY OF THE LIVER 
 
5.3.1 Volume of steatosis 
When analysing the H&E stained livers, the mean volume of steatosis was significantly lower 
in the Afriplex GRT™ treated groups (GRT and HFD-GRT) in comparison to the untreated 
groups (C- and HFD) (p = .02). The HFD fed groups (HFD and HFD-GRT) had significantly 
more steatosis than the C-group (both p < .001) (Figure 5.5 A). A decreased volume of steatosis 
in the GRT compared to the HFD-GRT groups was observed (both p < .001). Analysis of the 
Oil red O stained tissue showed a significant increase in steatosis in the HFD and HFD-GRT 
groups compared to the C- and GRT groups (p = .04);(Figure 5.5 B). However, the addition of 
Afriplex GRT™ did not significantly reduce steatosis in the HFD-GRT group. 
 
 
Figure 5.5: Volume of steatosis on the H&E (n=7 per group) (A) and Oil red O (n=5 per group) 
stained liver tissue (B). (C) control diet, (HFD) high-fat diet, (GRT) Afriplex GRT™ extract, (+) 
treated, (-) untreated. Vertical bars denote 0.95 confidence intervals. 
 
5.3.2 Image processing  
Image processing was used to determine the area of steatosis (converted to a percentage). In 
the H&E stained tissue steatosis was significantly higher in the HFD fed groups (HFD and 
HFD-GRT groups) in comparison to the control diet fed groups (C- and GRT groups); (p <.01). 
(Figure 5.6 A & Figure 5.7). The resultant hepatic tissue area was significantly reduced in the 
HFD and HFD-GRT groups in comparison to the C- and GRT groups (p = .029). Hepatic tissue 
was significantly lower in the HFD-GRT group in comparison to the C-group (p = .045) 
(Figure5.6 B & Figure 5.7). 
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The Oil red O tissue showed significantly less lipid deposits in the Afriplex GRT™ treated 
groups (GRT and HFD-GRT) in comparison to the untreated groups (C- and HFD); (p = .037). 
In contrast, significantly more lipid deposits were observed in the HFD fed groups (HFD and 
HFD-GRT) in comparison to the control fed groups (C- and GRT); (p < .001); (Figure 5.6 C 
& Figure 5.7). Hepatic tissue area was significantly lower in the HFD fed groups (HFD and 
HFD-GRT) in comparison to the control fed groups (C- and GRT); (p < .001); (Figure 5.6 D 
& Figure 5.7). The Afriplex GRT™ treated groups (GRT and HFD-GRT) showed significantly 
increased tissue area than the untreated groups (C- and HFD); (p = .038).  
 
 
Figure 5.6: Area of lipid deposits (A & C) and hepatic tissue (B & D) area in the H&E (n=7 per 
group) and Oil red O (n=5 per group) stained tissue. Two-way ANOVA, Games Howell post-hoc 
test. (C) control diet, (HFD) high-fat diet, (GRT) Afriplex GRT™ extract, (+) treated, (-) untreated. n=7 
per group. Vertical bars denote 0.95 confidence intervals. 
 
Micrographs histologically showing the differences between the groups are indicated in figure 
5.7. 




Figure 5.7: Liver tissue stained with H&E and Oil red O for morphometric measurements. C- 
and GRT group show normal morphology (H&E) with fatty deposits of less than 5%of the tissue. The 
HFD and HFD-GRT groups show fatty infiltration in both groups with the HFD group having 
ballooned hepatocytes (star) as well as micro (arrow head) and macrovesicular steatosis (star). H&E 
200x (Bar= 50μm), and oil red O stain 100x magnification (bar=100μm). (C) control, (GRT), Afriplex 
GRT™, (HFD) High-fat diet and (HFD-GRT) High-fat diet Afriplex GRT™ animals. 
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5.4 THE EFFECTS OF TREATMENT ON THE KIDNEY  
Kidney glomeruli and Bowman’s capsule size (μm2), proximal convoluted tubules and arcuate 
artery area, diameter and radius were determined for the various parameters measured. No 
significant differences were observed in the diameter and radii of the various structures 
measured (Addendum O, Table 20). Figure 5.8. illustrates the kidney glomeruli, Bowman’s 
capsules, and proximal convoluted tubules of the four study groups stained with H&E and 
periodic acid Schiff (PAS) stain. No distinct difference in renal corpuscle or PCT morphology 
was present between the four study groups. 
 
5.4.1 Glomeruli and Bowman’s capsule morphometry 
The size of the glomerulus and Bowman’s capsule was not significantly different across groups 
(Table 5.3). By subtracting the Bowman’s capsule and glomerular areas the renal space was 
determined. The HFD-GRT group showed a trend of smaller renal spaces in comparison to the 
C-group (LSD =.048) however, no statistically significant differences were observed. 
 
Table 5.3: Size and diameter (μm²) of the glomerulus, Bowman’s capsule and renal space. The 
renal space was smaller in the HFD-GRT group in comparison to the C-group (trend) however no 
significant differences were found in the size of glomeruli, Bowman’s capsule or renal space. Mean ± 
Standard error of the mean (SEM). 
Differing letters indicate significant differences, letters that are shared indicate no significant difference. 
(C) control, (GRT), Afriplex GRT™, (HFD) High-fat diet and (HFD-GRT) High-fat diet Afriplex 
GRT™ animals.  
 
 
C GRT HFD HFD-GRT 
Glomeruli 
Area (μm²) 7749.39±605.65 7272.31±658.53 7196.69±871.90 6303.47±571.61 
Diameter 97.818±3.879 94.303±4.338 92.683±6.789 87.568±4.094 
Bowman’s capsule 
Area (μm²) 10661.39±1415.71 8996.26±993.57 8848.55±1112.01 7610.39±744.40 
Diameter 114.03±7.57 104.15±6.60 102.39±8.12 96.07±4.82 
Renal space     
Area (μm²) 2912.01±906.95a 1723.95±414.53ab 1762.78±331.06ab 1318.14±277.68b 
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Figure 5.8: Kidney was stained with H&E for pathological evaluation and with periodic acid 
Schiff (PAS) stain to highlight the PCT brush border. No marked differences in morphology were 
seen between groups. Glomeruli (G), proximal convoluted tubules (P).(GRT), Afriplex GRT™, (HFD) 





















Stellenbosch University  https://scholar.sun.ac.za
69 
 
5.4.2 Proximal convoluted tubules 
A non-significant trend between the HFD-GRT group in comparison to the C-group, with the 
former showing smaller PCT outer surface areas (LSD =.048). No significant differences were 
found in the outer surface, luminal surface or the tubule wall areas between the four study 
groups (Table 5.4). 
 
Table 5.4: Morphometric parameters of the proximal convoluted tubules. A decreasing trend was 
observed in the HFD-GRT group in comparison to the C-group in PCT outer surface area. No significant 
differences were observed in the outer, luminal surface, tubule wall area or diameter. Data is expressed 








2766.99±377.85a 2334.46±238.49ab 2375.12±303.16ab 1941.00±155.33b 
Outer 
diameter 




525.06±87.72 523.21±51.17 410.61±58.58 382.78±43.80 
Luminal 
diameter 
23.63±2.14 23.63±0.83 21.63±1.83 19.86±1.25 
Wall area 2241.94±299.03 1811.25±221.64 1964.51±246.81 1558.22±145.90 
Wall 
diameter  
33.18±1.77 29.01±2.737 30.73±2.18 28.23±1.95 
Differing letters indicate trends, letters that are shared indicate no trends. Control (C), Afriplex GRT™ 
(GRT), High-fat diet (HFD) and High-fat diet Afriplex GRT™ (HFD-GRT) treated animals. 
 
5.4.3 Arcuate arteries 
The arcuate arteries outer and luminal surface areas, as well as the media to lumen ratio were 
determined (Table 5.5). The tunica media to lumen ratio differed between the HFD and GRT 
groups (LSD = .026) even though neither differed from the control. No significant differences 
were found in outer surface area, luminal surface area or media to lumen ratio. 
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Table 5.5: Morphometric parameters of the arcuate artery comparing the four study groups. A 
trend of smaller media to lumen ratio was observed in the HFD-GRT group in comparison to the C-
group although no significant differences were observed in any of the parameters measured. Data is 
expressed as mean ± standard error of the mean (SEM). 
Areas & 
diameters (μm²) 
C GRT HFD HFD-GRT 
Outer surface 
area  
5134.345±717.59 5967.046±847.08 4939.648±710.17 5026.925±767.13 
Internal diameter 39.25±3.26 39.62±3.42 42.63±4.38 37.71±3.60 
Luminal surface 
area  
2127.30±319.40 2186.17±354.17 2074.92±411.26 1864.43±370.53 
External 
diameter 
600.67±91.94 605.82±89.29 496.64±62.04 448.00±85.91 
Media area 1084.44±134.36 1219.22±188.019 897.882±88.10 886.89±153.24 
Media thickness 290.44±44.75 293.31±115.68 238.03±29.97 216.04 
Media: Lumen 
ratio 
11.88±0.73ab 13.2±0.75a 10.79±0.64b 11.46±0.75ab 
Differing letters indicate trends, letters that are shared indicate no trend. Control (C), Afriplex GRT™ 
(GRT), High-fat diet (HFD) and (High-fat diet Afriplex GRT™ HFD-GRT) treated animals. 
 
5.5 MORPHOLOGY AND PATHOLOGY OF THE PANCREAS, LIVER AND 
KIDNEY. 
The pancreas, liver and kidney (H&E) were sent to a veterinary histopathologist blinded to the 
allocation of study groups and treatments for analysis. A summary of the pathologist’s 
examination is provided in Addendum M. Additionally, the liver was scored using the NAS 
score (Kleiner et al., 2005) by five scorers. Evaluation of the liver by the NAS scorers and the 
histopathologist were compared. 
 
5.5.1 Pancreas  
The histopathologist noted the presence of active lymph nodes in the peripancreatic fat in the 
control and HFD groups more often than in the GRT and HFD-GRT groups (X² = 5.3317, 
p = .021) (Figure 5.9). A necrotic lesion was noted in a single GRT animal (one out of seven 
animals, 1/7); however, no additional lesions were found in any other group. Additionally, 
increased intra- and interlobular steatosis lesions were present in the HFD and HFD-GRT 
animals in comparison to the control and GRT groups. This was confirmed with the Oil red O 
stain (Figure 5.9). The acinar cells of the exocrine portion were normal. Mild periductal 
mononuclear cell infiltration was observed in the GRT (1/7) and HFD groups (2/7) however 
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this was not significant. A summary of the histopathologists findings is available in Addendum 
O Table 21. 
 
 
Figure 5.9: Pathology observed in the pancreas. (A) HFD group and (B) HFD-GRT group steatosis 
lesions (black arrows), (C) necrotic lesion observed in single animal (HFD-GRT animal) (as indicated 
by the dashed lines) and (D) peripancreatic fat active lymph nodules (as indicated by the dashed lines). 
All images 100X magnification. Bar represents 500um.  
 
5.5.2 Liver  
5.5.2.1 Non-alcoholic fatty liver disease (NAFLD) Activity Score  
This score evaluates steatosis, fibrosis and inflammation, hepatocyte pathology and assigns a 
diagnostic classification. Significantly increased values in the grade of steatosis (Figure 5.10 
A), microvesicular steatosis (Figure 5.10 B), and hepatocyte swelling (Figure 5.10 C) were 
found between groups. The presence of inflammation around the portal and lobular regions 
was increased in the HFD and HFD-GRT groups. The type of inflammatory foci, 
microgranulomas or lipogranulomas was also significantly increased. A summary of the 
steatosis and inflammatory lesions observed is shown in Figure 10 A-D. 
 




Figure5.10 Pathological lesions observed in the livers of HFD fed animals as evaluated by the 
Non-alcoholic fatty liver disease activity score (NAS). A)Hepatocytes with fat nitration and a 
microgranuloma of inflammatory cells. B) Microgranuloma and macrovesicular fatty infiltration in 
hepatocyte. C) Portal inflammation around the portal triad. D) Lipogranuloma with many hepatocytes 
with microvesicular steatosis and hepatocyte ballooning close by. CV:central vein; PT: portal triad; $: 
macrovesicular steatosis; star: microvesicular steatosis; #: inflammatory foci; arrow head: ballooned 
hepatocytes; arrows: glycogen deposits. 
 
5.5.2.2 Steatosis  
The HFD and HFD-GRT groups showed a significantly higher percentage of steatosis (grade 
2 or 3) in comparison to the control and GRT groups (grade 0) (p < .01). There was no 
difference between the control and GRT groups in terms of percentage of steatosis, however 
both groups differed from the HFD and HFD-GRT groups respectively (both p < .01); (Figure 
5.11 A). Microvesicular steatosis was significantly higher in the HFD and HFD-GRT groups 
(in comparison to the control and GRT groups (X² = 34.59, p < .01, df = 3) (Figure 5.11 B). 
Furthermore, the GRT group (1/7) had statistically more microvesicular steatosis than the 
control (0/7) (p = .005). Ballooning of hepatocytes was significantly higher in the HFD and 
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HFD-GRT groups (13/14) in comparison to the control and GRT groups (0/14, p < .01) (Figure 
5.11 C). No significant differences were observed in location of steatosis. 
 
Figure 5.11: Liver pathology was evaluated using the non-alcoholic fatty liver disease activity 
score (NAS): (A) percentage of steatosis, (B) microvesicular steatosis and (C) hepatocyte ballooning. 
Vertical bars denote 0.95 confidence intervals. (GRT) Afriplex GRT™ extract, (+) treated, (-) untreated. 




Using the NAS score, fibrosis was only observed in three animals, one animal each from the 
control, HFD and HFD-GRT groups (3/28). No additional fibrosis was scored and thus no 










































































































More inflammatory foci were observed in the region of the portal triads than within the lobes 
of the liver. Inflammatory foci were observed around the portal areas in the HFD and HFD-
GRT groups (8/14) than the control and GRT groups (3/14); (Chi-square = 13.46, p < .01, 
df = 3);(Table 5.6). The HFD-GRT group (3/7) showed significantly less portal inflammation 
than the HFD group (5/7). Inflammatory portal lesions were observed in the GRT (2/7) and the 
C-group (1/7). Lobular inflammation differed significantly between the control and HFD fed 
groups (p < .01). Microgranulomas were present in the HFD (50%), GRT (30%) and HFD-
GRT (60%) groups. More microgranulomas were observed in the HFD and HFD-GRT groups 
than the control and GRT groups (X² = 12.26, p = .02, df = 3). No lipogranulomas were 
observed in the control or GRT groups. In contrast, significantly more foci were present HFD 
and HFD-GRT groups (5/7 and 4/7 respectively) in comparison to the control and GRT groups 
(both 0/7) (Chi-square = 15.33, p < .01, df = 3);(Table 5.6).  
 
Table 5.6: Inflammatory parameters scored using the non-alcoholic fatty liver disease activity 
score (NAS). The presence of inflammatory lesions in the various study groups expressed as 
percentages per group. 
Percentage (%) C GRT HFD HFD-GRT 
Lobular inflammation 0a 5a 17b 17b 
Portal inflammation 10a 20ab 80c 50bc 
Microgranulomas  0a 30ab 50b 60b 
Lipogranulomas 0a 0a 50b 40b 
Differing letters indicate significant differences, letters that are shared indicate no significant difference. 
 
5.5.2.5 Interobserver reliability NAS score 
Six observers including the scores given by the histopathologist were compared. The agreement 
between scorers κ = 0.43, which concludes that moderate agreement was observed between 
observers.  
 
5.5.3 Liver architecture (structural integrity) 
Collagen type-3 fibres (Reticulin) form the structural network in the liver whereas collagen 
type-1 fibres are usually associated with fibrotic change. Structural architecture was evaluated 
using the Gordon and Sweet’s reticulin impregnation technique while fibrotic changes were 
evaluated using the Masson’s Trichrome technique (Refer to Figure 5.12). The HFD group 
showed extensive hepatocyte ballooning and sinusoidal invasion with very few reticulin fibres 
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present (< 5%) apart from around the central vein and portal tracts. With Afriplex GRT™ 
treatment, the HFD-GRT group showed a reticulin network with less fragmentation and semi-
complete fibres (> 60%). The HFD-GRT reticulin architecture resembled the C-group apart 
from some deviations associated with hepatocyte ballooning and steatosis in the central region 
(zone 3). The C- and GRT group livers were indistinguishable, both showing a normal 
architectural profile with little to no reticulin fibres fragmentation (Figure 5.12). Fibrotic 
changes were present in a few animals (3/28) and no pattern could be determined (Figure 5.12) 
 




Figure 5.12 Liver tissue stained with Masson’s trichrome and Gordon and Sweet’s Reticulin stain 
for pathological evaluation. Fibrotic changes were sporadic, and no pattern was found. Reticulin 
architecture was substantially affected by HFD exposure however, the HFD-GRT group showed less 
fragmentation than HFD group. Masson’s trichrome 200x (Bar= 50μm), and G&S reticulin 100x 
magnification (bar=100μm). (C) control, (GRT), Afriplex GRT™, (HFD) High-fat diet and (HFD-
GRT) High-fat diet Afriplex GRT™ animals.5.5.2.6 Histopathologist 
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Significant lipid vacuole degeneration was reported by the histopathologist in the HFD and 
HFD-GRT groups than the control and GRT groups (p < .01). No other statistically significant 
differences were found observed. A summary of the histopathologists findings is available in 
Addendum O Table 21. 
 
5.5.4 Kidney 
5.5.4.1 Pathology review and Histopathologists findings 
The kidney was evaluated for renal tubular nephrosis, intratubular oedema, proteinaceous 
luminal material and congestion. No significant differences were found. A summary of the 
histopathologists findings is available in Addendum O Table 21. 
 
5.6 SUMMARY  
In the present study, significantly decreased body mass in the HFD-GRT compared to the HFD 
group was observed. Pancreas, liver and kidney mass significantly decreased in the HFD-GRT 
group compared to the C-group. Pancreatic islets size, α- and β-cells area decreased in the 
HFD-GRT group compared to the C-group. Increased volume and area of steatosis was 
observed in the HFD groups compared to control diet fed groups. In terms of pathology 
increased grade of steatosis, presence of microvesicular steatosis, hepatocyte ballooning and 
inflammation in the liver of the HFD group. A trend, smaller media-to-lumen ratio in the HFD 
compared to the GRT group was observed. 
 
In contrast, Afriplex GRT™ significantly reduced BM, liver mass, volume of steatosis (both 
H&E and Oil red O), decreased kidney mass, decreased active peripancreatic lymph nodes. 
Smaller renal spaces and proximal convoluted tubules were observed in Afriplex GRT™ 
treated groups however these were only trends.  
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The anti-obesity effects of fermented rooibos (Beltran 2011; Sanderson 2014), and its 
polyphenolic compounds (Jung et al., 2013; Mathijs et al., 2014; Liu et al., 2015; Son et al., 
2013) have been described. Afriplex GRT™ is a laboratory standardized unfermented (green) 
rooibos extract which has a high aspalathin content (12.8%) (Beelders et al., 2012). Limited 
studies have evaluated unfermented green rooibos extracts as the development of this form of 
rooibos was only established in 1990 (Vilano et al., 2010; Joubert & de Beer, 2011; Muller et 
al., 2012; Mazibuko et al., 2013; Kamakura et al., 2015; Mazibuko et al., 2015; Kroukamp, 
2018; Maqeda, 2018). There is disagreement with regards to the use of individual rooibos 
polyphenols (Snijman et al., 2007; Kawano et al., 2009; Perold et al., 2009) compared to 
complete rooibos extracts, as the latter may be more effective due to the synergistic effects 
produced by the combination of polyphenols in extracts (Canda et al., 2014; Joubert & de Beer, 
2011; Muller et al., 2017). In the present study, an aspalathin-rich unfermented extract was 
used to evaluate the synergistic effects of a complete extract in an obese rat model. As previous 
extracts and pharmaceuticals can be unpalatable, a jelly block medium was used. The 
effectiveness of the Afriplex GRT™, an unfermented rooibos extract in the present study, could 
be related to the jelly medium by which it was administered to animals. A few authors have 
previously used jelly blocks as a medium to administer different drug and polyphenol 
treatments (Lilies et al., 1997, Chellan et al., 2008, Huisamen et al., 2013, Symington et al., 
2017). The use of jelly mediums may be so effective because of compliance and precise dose 
control which it ensures (Huisamen et al., 2013). A disadvantage of the jelly blocks is the 
additional sugar content. In the present study, animals each received a single jelly block 
containing the Afriplex GRT™ or placebo jelly blocks to control the sugar content received by 
each animal.  
 
Dietary, pharmaceutical and genetic adaptations are frequently used to produce obese animal 
models which replicate the conditions seen in humans (Buettner et al., 2007). High-fat diets 
(HFD) promote hyperglycaemia, insulin resistance and compromise β-cell function (Buettner 
et al., 2007), induce hepatic steatosis, increase body and organ mass (Beltran-Debon et al., 
2011) and promotes glomerulopathy and tubular injury (Altunkaynak et al., 2008) in various 
rodent models. The HFD in the present study, was readily consumed by the animals seemingly 
because of how sweet and moist the diet was. As rats have been shown to like sweet tasting 
things (Chellan et al., 2008), the addition of fructose in the present study’s HFD may have 
prompted animals to consume more food. Lenoir et al. (2007) reported that consumption of 
diets high in sugar is motivated by the sweetened taste. As the HFD had a higher moisture 
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content, these animals subsequently drank less water and showed increased food intake in 
comparison to the control-diet fed groups (C and GRT groups) (Maqeda, 2018). This resulted 
in increased water intake in the control fed groups in comparison to the HFD fed groups.  
 
As the present study formed part of a larger project testing Afriplex GRT™ in a HFD fed model 
some interesting results from the larger project pertaining to the present study are briefly 
discussed. The studies completed found that Afriplex GRT™ improved oral glucose tolerance, 
improved whole-body insulin resistance and enhanced mitochondrial function (Kroukamp, 
2018). Whereas in the study conducted by Maqeda, (2018) hypertension decreased, vascular 
function, the liver antioxidant profile, and glucose metabolism improved in the HFD-GRT 
animals. Both studies reported decreased body, liver and intraperitoneal fat masses as well as 
serum leptin levels in the HFD-GRT animals. Therefore, the present study, wanted to confirm 
whether the ameliorative adaptations in the HFD-GRT animals were observed in the histology 
and morphometry of the pancreas, liver and kidney. 
 
6.1 BODY AND ORGAN MASS  
In animal models, a HFD is frequently associated with an increase in body mass (BM) (Noeman 
et al., 2011; Park et al., 2012; Schultz et al., 2013; Anyakudo et al., 2015; Fraulob et al., 2010) 
as was seen in the HFD group of the present study. Beltran et al. (2010) reported a decreased 
BM in control and HFD (40% fat) fed animals treated with a fermented rooibos extract for 14-
weeks. Similarly, in the present study, significantly lowered BM was seen in the Afriplex 
GRT™ groups (GRT and HFD-GRT) treated for 16-weeks. However, controversy exist in the 
literature regarding the effects of rooibos and rooibos polyphenols on BM (Jung et al., 2013; 
Liu et al., 2015). Quercetin, a component of Afriplex GRT™ (0.57%), effectively decreased 
BM gain in C57BL/6J mice fed an HFD for nine-weeks (Jung et al., 2013). Whereas in ApoE 
mice fed an HFD for 24-weeks, quercetin had no effect on BM, liver mass or the serum lipid 
profile (Liu et al., 2015). The latter study had a longer treatment period and different animal 
model than Jung et al. (2013) which could explain the discrepancy between studies as similar 
HFD and quercetin suppliers were used. As the present study, used an extract containing 
quercetin, our findings agree with that of Jung et al. (2013), the action of quercetin in Afriplex 
GRT™ may have effects on BM of male Wistar rats fed a HFD for 16-weeks. Many studies 
reported no effect on BM with various rooibos extracts and polyphenols in various animal 
models. These included (Z)-2-(β-D-glucopyranosyloxy)-3-phenylpropenoic acid (PPAG) 
(Mathijs et al., 2014) aspalathin or green rooibos (Watanabe et al., 2014), a 2% and 5% 
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unfermented rooibos extract (Opuwari & Monsees, 2013; Monsees & Opuwari, 2016) or 
fermented rooibos extracts (Smith & Swart, 2016). Baba et al. (2009) and Canda et al. (2014) 
reported no significant changes in BM in animals fed various rooibos supplements, including 
unfermented rooibos treatments in animals on a control diet. Furthermore, an aspalathin-
enriched green rooibos extract had no effect on BM in male Fisher rats fed a control diet for 
28 days however over 90 days a significant decrease in liver and body mass was observed (Van 
der Merwe et al., 2015). As decreased BM was observed in the HFD-GRT group in the present 
study, Afriplex GRT™ may have potential as a therapeutic agent against diet-induced obesity. 
 
In the present study, pancreatic mass was expressed as a percentage of body mass to normalize 
any changes in tissue mass to the whole animal. Even though exposure to an HFD is associated 
with an increase in pancreas mass (Carter et al., 2014; Fraulob et al., 2010; Anyakudo & 
Omotayo, 2015, Yagahashi et al., 2016), pancreatic mass in the present study was not 
significantly increased by the HFD. Similarly, He et al. (2010) showed no change in pancreas 
mass associated with an HFD when the diet contained 60% calories from fat. In contrast, to 
fermented rooibos (Beltran-Debon et al., 2011), pancreas mass in the present study was 
significantly decreased in the GRT and HFD-GRT groups. The decreased organ mass in the 
HFD-GRT group could relate to decreased intraperitoneal fat mass reported in the same 
animals as in the present study (Maqeda, 2018). The decrease in intraperitoneal fat mass 
suggests less adipose tissue, overall. The decreased adipose tissue mass could be related to 
restoration of specific cell signalling molecules which may be linked to aspalathin. Aspalathin 
is hypothesized to increase adenosine monophosphate protein kinase (AMPK) and protein 
kinase B (PKB) during glucose metabolism and translocation into cells (Muller et al., 2012; 
Son et al., 2013; Kamakura et al., 2015). In the present study, as Afriplex GRT™ contains 12% 
aspalathin it may have increased AMPK and PKB signalling resulting in reduced ectopic fat 
deposition and tissue mass. 
 
In obese humans and rats, the liver may act as ectopic fat storage which results in increased 
liver mass. Fraulob et al. (2015) and He et al. (2010) both reported an increase in liver mass in 
C57BL/6J mice fed an HFD. Similarly, in the present study, an increase in liver mass was 
observed in the HFD fed animals. However, in the HFD-GRT animals’ liver mass was 
significantly decreased compared to the HFD group. Few articles agree that rooibos and its 
extracts effectively decrease liver mass (Beltran-Debon et al., 2011; Jung et al., 2013) however 
some extracts have shown increased or negligible effects on liver mass (Opuwari & Monsees, 
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2013; Canda et al., 2014; Monsees & Opuwari, 2016). In agreement with the present study, a 
decrease in liver mass was reported in control and HFD fed mice treated with a fermented 
rooibos extract (Beltran-Debon et al., 2010) and quercetin (Jung et al., 2013). As the Afriplex 
GRT™ extract used in the present study contained quercetin, the decreased liver mass seen by 
Jung et al.(2013) is similar to what was observed here. In contrast, increased liver mass was 
observed with a 2% and 5% unfermented rooibos solution in female Wistar rats (Monsees & 
Opuwari, 2016). Whereas a 2% unfermented solution had no effect on liver mass in male 
Wistar rats fed a standard rat chow diet (Canda et al., 2014). Similarly, Opuwari and Monsees 
(2013) reported no effect on liver mass (absolute or relative to BM) in male Wistar rats with 
either a 2% or 5% unfermented rooibos extract.  
 
In contrast to the liver mass, the animals in the present study showed a decrease in kidney mass 
in the HFD fed animals (HFD and HFD-GRT). Increased renal mass was reported in rats fed 
an HFD (60% and 45% fat respectively) for six-weeks (Crinigan et al., 2015) and 52-weeks 
(Van Der Heijden et al., 2015) respectively. In diabetic individuals, decreased renal mass is 
common and is associated with renal disease progression (Tobar et al., 2013). Therefore, the 
decreased kidney mass in the present study may indicate diabetic related changes in the kidney. 
This is supported by changes in glucose tolerance in the HFD group confirmed by Maqeda 
(2018) and Kroukamp (2018). In the present study, a substantial decrease in kidney mass was 
seen in the Afriplex GRT™ treated groups. In contrast, a 2% and 5% unfermented rooibos 
extract showed no effect on kidney mass in female rats on a control diet (Monsees & Opuwari, 
2016) whereas in male rats 5% fermented and unfermented rooibos extracts respectively, 
significantly decreased kidney mass relative to BM (Opuwari & Monsees, 2013). In the HFD-
GRT group, decreased renal mass could indicate increased glomerular capillary pressure and 
possible diabetic changes which indicates renal disease progression. Therefore, the changes in 
renal mass in the HFD-GRT group may have illustrated an antagonistic interaction between 
Afriplex GRT™ and the HFD as well as differences in moisture content in the diets; however, 
further studies will need to confirm this. 
 
Pancreas, liver and kidney mass were decreased with Afriplex GRT™ treatment in control and 
HFD fed animals (GRT and HFD-GRT groups respectively). The decrease in organ mass in 
the present study could be related to the inhibitory action of aspalathin and quercetin on 
adipogenesis and adipocyte metabolism in vitro (Sanderson et al., 2014) and in vivo (HFD fed 
rats) (Moon et al., 2013). Thus, the decrease in body and organ mass may be related to 
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inhibition of adipogenesis by aspalathin and/or quercetin components of the Afriplex GRT™ 
extract studied here.  
 
6.2 PANCREATIC MORPHOMETRY, MORPHOLOGY AND PATHOLOGY 
As pancreatic islets are the functional units of the endocrine pancreas, increased islet areas in 
the GRT group suggest increased hormone secretion from the pancreas especially insulin (Kim 
et al., 2009). However, smaller islets are associated with increased insulin, as was seen in the 
HFD-GRT group. Furthermore, the HFD-GRT group had increased islet numbers and islets 
per section area were observed. Thus, two opposing theories can be proposed namely islet 
neogenesis or lipotoxicity. As larger islets were present in the GRT group in comparison to the 
C-group, islet (β-cells) neogenesis may have occurred (Sasaki et al., 2018). Neogenesis 
postnatal in rats has been reported and is associated with pancreatic hormone-positive cells 
budding from the pancreatic duct epithelium (Bonner-Weir et al., 2012). Lipotoxicity has been 
associated with a HFD, however, in the present study the increased islets per section area and 
marginally decreased islet, α- and β-cell areas were not sufficient to say lipotoxicity was 
present. However, in the HFD-GRT group, as the islet and β-cell areas were significantly 
decreased this suggests lipotoxicity occurred. In the HFD-GRT animals, improved glucose 
tolerance was suggested based on the oral glucose tolerance tests (Maqeda, 2018). Thus, the 
effect physiologically was reflected histologically on the pancreatic islets.  
 
As α-cell area fell within the range of 12-15% in the present study, this is well within the normal 
range of 10-15% for rodents (Steiner et al., 2010). Animals fed an HFD usually present with 
increased β-cell areas (Oliveira et al., 2014, Falcoa et al., 2016). Oliveira et al. (2014) saw no 
change in islet and β-cell areas in HFD treatment lasting for 30 days. However, when mice 
were fed the diet for 60 days a significant increase in islet areas, β-cell areas and islets per 
section area in male C57BL6/J0Unib mice was observed. In contrast, in the present study, no 
significant changes were observed in β-cell areas and islets per section area in the HFD group 
in comparison to the C-group. A component of Afriplex GRT™ namely PPAG, has been 
associated with increased β-cell mass in animals treated with an HFD (Mathijs et al., 2014) and 
in response to streptozotocin (STZ) in Balb/c mice (Himpe et al., 2016). In contrast, the HFD-
GRT group in the present study, had smaller islets (and β-cell areas) which may indicate that 
this diet was more noxious due to the addition of fructose. Fructose does not activate the 
pancreatic β-cells (Elliot et al., 2002). The lack of a stimulus to β-cells disrupts the insulin 
signalling pathway (Schultz et al., 2013) and therefore afferent signals which control food 
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intake and weight gain are not activated (Meisser et al., 2007). In the present study, the HFD 
animals had fewer β-cells than the control animals and this may be linked to the lack of β-cell 
activation by fructose in the HFD. 
 
Pathology within the pancreas was minimal apart from the presence of pancreatic steatosis and 
active lymph nodes in the HFD groups. Pancreatic steatosis was confirmed with Oil red O 
staining on frozen sections and has similarly been reported in other HFD models (He et al., 
2010; Carter et al., 2014; Fraulob et al., 2010). In the present study, inter- and intralobular 
steatosis was noted in the all four study groups, with the HFD and HFD-GRT groups presenting 
with excess ectopic fat deposition within the pancreatic lobules and periodically near the 
pancreatic islets. The presence of active lymph nodes was significantly less in the GRT and 
HFD-GRT groups. This could be linked to the anti-inflammatory properties associated with 
rooibos (Baba et al., 2009; Ajuwon et al., 2013; Canda et al., 2014).  
 
6.3 LIVER MORPHOMETRY, MORPHOLOGY & PATHOLOGY 
Schultz (2013) and Catta-pretta (2011) both reported an increase in the volume and area of 
steatosis in male C57BL/6J mice fed a HFD in comparison to the control fed groups. In 
agreement with the fore mentioned studies, the volume and area of steatosis was increased in 
the HFD fed groups in the present study. For the assessment of steatosis analysis of the Oil red 
O stained tissue is regarded as more accurate than that of H&E stained tissue (Levene et al., 
2012, Schultz et al., 2013). However, as H&E stained tissue is more readily available than 
frozen tissue it can easily be compared retrospectively (Levene et al., 2013). Although, future 
studies assessing steatosis should aim to obtain frozen tissue as this is the most accurate 
technique. 
 
In the present study, both micro-and macrovesicular steatosis were present while the latter was 
more common in the HFD groups. Steatosis in the HFD-GRT animals showed microvesicular 
steatosis which indicates a possible restorative effect associated with rooibos. Various studies 
have evaluated the presence of these steatosis lesions within the liver of rats fed a HFD 
(Beltran-Debon et al., 2010; Park et al., 2012; Fraulob et al., 2010). Beltran et al. (2010) 
showed the decrease of hepatic steatosis with a fermented rooibos extract which may explain 
the reduced steatosis in the HFD-GRT group in the present study. A decrease in the grade of 
steatosis and the degree of hepatocyte ballooning in the HFD-GRT was observed in comparison 
to the HFD group. This indicates a healthier profile and a possible restorative effect of Afriplex 
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GRT™ in HFD animals. This is further prompted by the presence of more microvesicular than 
macrovesicular steatosis in the HFD-GRT group as the former can be reversed. 
 
In the present study, portal inflammation and lipogranulomas were reduced in the HFD-GRT 
group, however increased inflammatory lesions were observed in the GRT group suggesting 
that GRT may stimulate an inflammatory response. As the animals in the present study had 
characteristics of obesity they were predisposed to oxidative stress and inflammation (Noeman 
et al., 2011). Rooibos and its extracts have shown anti-inflammatory potential (Scholms et al., 
2012; Baba et al., 2009). The increased inflammatory lesions observed in the GRT group in 
the present study are contrary to the effects of fermented rooibos which have shown to decrease 
inflammatory cytokines levels in control fed male Wistar rats (Smith & Swart, 2016). The 
marginally increased inflammatory lesions in the GRT group may be related to the large 
number of antioxidants (polyphenols) contained in rooibos and its extracts. Baba et al. (2009) 
reported increased tissue inflammation associated with antioxidants (SOD) levels in rooibos 
treated rats and related this to the increased number of flavonoids found in rooibos.  
 
In the present study, evaluation of the Gordon and Sweet’s reticulin stain, showed less 
fragmentation in structural architecture reticulin fibres in the HFD-GRT in comparison to the 
HFD group. The improvement in structural integrity can be related to reduced steatosis in the 
HFD-GRT group in comparison to the HFD group. Similarly, Singhi et al. (2012) reported 
improved reticulin architecture in areas where less steatosis was present in human studies. As 
rooibos and its extracts have been suggested as antilipidemic agents (Beltran et al., 2011; 
Sanderson et al., 2014; Jung et al., 2013) the decreased steatosis and hepatocyte ballooning in 
the HFD-GRT group, may have put less strain on the reticulin network resulting in in improved 
morphology. In terms of fibrosis, only three animals presented with fibrosis, an essential 
marker for progression of fatty liver disease. However, as the liver is a regenerative organ, the 
lack of fibrosis at the end of experimentation suggests reversal and or prevention of fibrotic 
change as a result of Afriplex GRT. Whether Afriplex GRT™ can effectively reduce steatosis 
and inflammatory conditions including fibrotic changes (not seen in the present study) requires 
further investigation.  
 
6.4 KIDNEY MORPHOMETRY, MORPHOLOGY AND PATHOLOGY 
Marked renal structural remodelling including glomerulosclerosis and tubular injury 
(Altunkaynak et al., 2008) is associated with diet-induced obesity yet in the present study 
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extensive renal corpuscle pathology was not observed. Furthermore, in the present study, the 
glomerular surface area was not significantly increased by an HFD. Contrastingly, glomerular 
surface area was increased in mice fed a HFD for 12-weeks and further glomerulomegaly was 
observed in the same animals at 16-weeks (Ruggiero et al., 2011). In the present study, the 
HFD was assigned for 16-weeks however the glomerular and Bowman’s capsule areas and 
diameters were decreased in the HFD group. In addition, no glomerular pathology was noted. 
The lack of changes in the present study are contrary to the literature as well as findings in the 
liver and pancreas where the effects of fructose contained in the HFD produced some 
detrimental effects.  
 
Decreased glomerular and Bowman’s capsule size was noted in the Afriplex GRT™. Pereira. 
(2017) studied the renal corpuscle (glomeruli and Bowman’s capsule) and proximal convoluted 
tubules of rats supplemented with a 2% fermented rooibos extract. No significant effects were 
determined although larger glomerular and Bowman’s capsule areas and diameters were 
reported in the rooibos treated rats. Similarly, in the present study, no significant changes were 
observed in glomerular and Bowman’s capsule areas and diameters. In control fed female 
Wistar rats treated with a 5% fermented rooibos extract no deviations in kidney morphology 
were observed however an increased creatinine level was present (Monsees & Opuwari, 2016). 
As no kidney function tests were performed, no conclusion can be determined on whether 
Afriplex GRT™ is detrimental on the kidney.  
 
The renal space, proximal convoluted tubules (PCT) and arcuate arteries were not significantly 
altered in the present study. In non-diabetic obese individuals, the renal space is increased, 
which may be a consequence of glomerular hyperfiltration (Tobar et al., 2013). Similar to the 
effects on renal mass the effects seen in the renal space, PCTs and arcuate arteries in the HFD-
GRT group may indicate synergistic or antagonistic effects of Afriplex GRT™ and an HFD.  
 
In sustained hypertension a morphological increase in both arterial media-to-lumen ratio and 
wall thickness is expected (Laurent, 1995). In contrast, in the present study, a trend of smaller 
media-to lumen ratio in the HFD group in comparison to the GRT group was observed. As 
neither group was significantly different from the C-group, the arcuate arteries were not 
morphologically adapted by the HFD or Afriplex GRT™ treatment. In the HFD animals in the 
present study, hypertension was confirmed by increased mean systolic, diastolic, arterial 
pressure, and increased aortic ring tension all of which were improved in the HFD-GRT 
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animals (Maqeda, 2018). Previously, anti-hypertensive characteristics of rooibos in vivo and in 
vitro have been suggested.(Person et al., 2010) Therefore, Afriplex GRT™ may possess 
promising effects on hypertension not reflected on the histomorphometry of the arcuate artery.  
 
Contrary to the literature, glomerulopathy such as focal segmental glomerulosclerosis or 
glomerulomegaly which are commonly seen in rats fed an HFD (Tobar et al., 2013) was not 
observed in the present study. Stemmer et al. (2012) reported the presence of proteinaceous 
cast, monocyte infiltration, slightly basophilic tubules, glomerulosclerosis and basement 
membrane thickening in male Wistar rats. Gai et al. (2014) reported increased fibrosis, 
glomerular pathology and interstitial fibrosis in C57/BJ mice fed an HFD of 20-weeks. Lastly, 
glomerulomegaly with the absence of albuminuria and podocyte loss was observed in mice fed 
an HFD (Wicks et al., 2016).  
 
Thus, the decrease in kidney mass and parts of the nephron suggest overall that Afriplex GRT™ 
treatment may negatively affect the kidney. However, with an increased study period alternate 
results may have been observed. Kidney function tests such as the urine albumin-creatinine 
ratio and serum creatinine values would explain if histomorphometric effects of Afriplex 
GRT™ related to changes in kidney function as well. The mild histomorphometric and minimal 
pathology observed in the present study contradicts the effects known to occur in conjunction 
with an HFD. 
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In conclusion, this study demonstrates that Afriplex GRT™ may possess anti-obesity 
properties as demonstrated by the significant decrease in body mass as well as liver mass in the 
HFD fed animals. Further study is required to investigate the mechanism of action that Afriplex 
GRT™ has on pancreas and kidney mass and to determine whether the decrease in mass in the 
control fed GRT group was harmful.  
 
This study postulates that neogenesis or lipotoxicity were present in the pancreata of HFD-
GRT group due to the presence of increased islet numbers and islets per section area in the 
same group. As the GRT group showed increased islet and β-cell areas, this may have indicated 
proliferation of the pancreatic islets. However, as the HFD group had decreased islet numbers 
and marginally decreased islet and β-cell areas, the addition of fructose to the diet may be toxic 
to pancreatic islets as was seen in the literature. Therefore, in the HFD-GRT group, the addition 
of antioxidants by Afriplex GRT™, may have reduced oxidative stress and lipotoxicity induced 
by the HFD. This allowed more islets to be present and improved glucose tolerance of the same 
animals studied presently. The changes observed require further investigation of β-cell 
proliferation, function, apoptosis as well as determination of pancreatic lipases. 
 
As Afriplex GRT™ successfully decreased liver mass, the volume and area of steatosis, it may 
be promising as a hepatoprotective supplement against obesity associated non-alcoholic fatty 
liver disease (NAFLD). Reduced steatosis, inflammation and improved architecture in the liver 
further promote this product as an anti-obesity agent in the liver. In the present study, fibrosis 
was only observed sporadically suggesting reversal of NAFLD. As liver tissue was only 
evaluated at the end of the 16-week study period, changes seen during the study period cannot 
be confirmed, including the presence of fibrosis. Additional staining with Sirius red instead of 
Masson’s trichrome could assist detection of minute fibrotic changes. Therefore, a study period 
with periodic investigation of tissue over a longer study period may detect NASH changes 
associated with a HFD and better illustrate the ameliorative effects of Afriplex GRT™ on 
NAFLD.  
 
In the kidney Afriplex GRT™ decreased kidney mass, components of the renal corpuscle 
(glomerular and Bowman’s capsule), proximal convoluted tubules and arcuate arteries. 
Whether these affects were negative cannot be substantiated as kidney function tests were not 
performed namely albumin and creatinine levels.  
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Thus, Afriplex GRT™ may possess observable ameliorative effects on the histomorphometry 
of the liver. Whether the changes on the pancreas and kidney were ameliorative is inconclusive. 
However, in the pancreas Afriplex GRT™ may improve pancreatic islet numbers leading to 
improved glucose tolerance as seen physiologically. Additional tests of the pancreas and kidney 
are required to be able to substantiate the effects seen in the present study and further elaborate 
on the effects of Afriplex GRT™. Afriplex GRT™ reduced pathology in the pancreas and liver 
as shown by decreased steatosis and hepatocyte ballooning in the liver as well as the presence 
of active lymph nodes in the pancreas and inflammatory foci in the liver, respectively.  
 
The use of green rooibos as a natural supplement drug is possible. Afriplex GRT™ is available 
as a powder and therefore addition of it to food and liquids is possible. Green rooibos is also 
available in many supermarkets however, the effects of green rooibos at cup of tea strength 
may not be as effective. The use of Afriplex GRT™ as an anti-steatotic agent along with 
healthy eating (dieting) may be effective in weight loss. In the present study, Afriplex GRT™ 
reduced body mass (organ and intraperitoneal fat mass) suggests a promising effect for many 
wanting to lose body mass. In obesity, the problem is regaining the body mass after losing it. 
Afriplex GRT™ may be effective for these patients as in the present study (HFD-GRT group) 
no toxic effects were reported. Three studies have confirmed hepatotoxicity with excess 
consumption of rooibos and therefore chronic consumption should be done with caution and in 
conjunction with a dietician or medical professional. The effectiveness of this extract in the 
present study calls for further study in other animal models and possible clinical trials. 
 
Limitations and future studies 
 
Afriplex GRT™ is a stable powder unfermented rooibos extract however, future researchers 
should determine whether the polyphenol content was affected by the jelly medium used in this 
study. As ameliorative effects were observed in this study the polyphenol levels were sufficient 
to produce effects on tissue histomorphology. Although understanding of why this medium 
was effective may improve other vehicles of treatment and the translation of this medium into 
a product.  
 
To ensure efficient use of animals, tissue was shared with the Division of Medical Physiology, 
Stellenbosch University. This affected the amount of pancreatic tissue available for 
histomorphometry. Future research should aim to study a specific portion of the pancreas as 
Stellenbosch University  https://scholar.sun.ac.za
91 
 
changes in the distribution of islets differs in different regions of the pancreas. Pancreatic 
studies should also determine pancreatic β-cell mass, function, the presence of apoptotic 
markers and pancreatic lipases expression. As this will help explain changes observed in the 
HFD-GRT group. As the pancreas has very few endogenous antioxidants, evaluation of the 
antioxidants profile in the HFD-GRT animals may explain how Afriplex GRT™ improved 
glucose tolerance.  
 
The study-period employed in the present study, caused increased body and liver mass as well 
as hepatic steatosis (signs of obesity). However, study of these changes at periodic intervals 
e.g. 4, 8, 12 and 16 -weeks or over a longer period may determine whether fibrotic changes had 
taken place in the liver (as it is regenerative) and were absent as tissue samples were only taken 
at the endpoint of the study. Furthermore, staining with Sirius red may assist detection of 
minute fibrotic changes. Afriplex GRT™ significantly reduced steatosis in the liver, 
determination of the liver lipid profile (very-low density lipoproteins, low density lipoproteins, 
high density lipoproteins) will detect deviations in the type of lipids present in the different 
groups. In addition, study of the inflammatory cytokines will explain the immune systems role 
in the function of Afriplex GRT™.  
 
For the kidney, plasma albumin-creatinine ratio and serum creatinine levels should be 
performed to determine kidney function. Changes in the histomorphometry are inconclusive as 
statistical power was not sufficient due to the small sample number. The addition of these 
functional (blood) tests as well as the investigation of endogenous antioxidants will indicate 
whether Afriplex GRT™ has a protective effect on the kidney. The addition of the Cavalieri 
principle to estimate glomerular volume may provide more details on the glomeruli and 
whether Afriplex GRT™ induced a protective effect in HFD fed animals. A longer study time 
period may allow the effects of the HFD and Afriplex GRT™ to be seen on a histological level. 
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Addendum B: Materials  
 
Table 1: Materials used in study. 
Materials  Company  
Animal feeds  
Rodent breeder feed (Control feed) Nutritionhub (Pty) Ltd, Stellenbosch, South 
Africa  
High-fat diet  
Rodent breeder feed 390 g Nutritionhub (Pty) Ltd, Stellenbosch, South 
Africa 
Condense milk Nestle™ 
Cholesterol 10 g Merck 
Holsum cooking fat 400 g  Animal Unit 
Casein 100 g Merck 
Boiling water 200 ml - 
Fructose 100 g Merck 
Afriplex GRT™ supplement  




Blue top collection tubes  -  
Gloves  -  
Plastic Eppendorf tubes 1 mL  -  
Scalpel  -  
Scissors  - 
Tweezers  - 
Weighing boats - 
Electronic scale - 
Zip lock bags - 
Histology  
Aqueous mounting media Kimix 
Cover slips (24 x 32 mm)  -  
Cover slips (24 x 50 mm)  -  
Clear nail varnish - 
Double frosted glass microscope slides  Kimix, Cat: 7107  
Embedding cassettes  SPL Lifesciences (Pty) Ltd Cas: 400600  
Low profile microtome blades  Leica microsystems (Pty) Ltd, Germany  
Paraffin wax (Embedding wax)  Leica Microsystems (Pty) Ltd Cat: 39602012  
Plastic specimen jaws  SPL Lifesciences (Pty) Ltd Cas: 400600  
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Materials  Company  
Positively charged microscope slides  Merck- (Pty) Ltd Cat no: S001  
Moisture chamber - 
Reagents  
10% Formaldehyde  Merck (Pty) Ltd Cat: 47608  
Acid Fuschin  Merck- (Pty) Ltd  
Dextrin from potatoes starch 9004-53-9, Merck Chemicals, (Pty), Ltd 
DPX mounting media  Associated Chemical Enterprises Batch: 
30773  
Eosin Yellowish  SAAR218600DC, Merck Chemicals (Pty) 
Ltd., Gauteng, South Africa  
EnVision™ G/2 Double stain system, 
Rabbit/mouse (DAB+/Permanent red 
K5361, Dako, Denmark, Inc  
Ethanol 99%  Merck- Cas: 64-17-5  
Ferrous sulphate  Merck- Cas: 127-03-55  
Glacial Acetic acid  Merck- Cas: 10005706  
Hydrogen Peroxide  Merck (Pty) Ltd, Modderfontein, Gauteng  
Mayer’s Haematoxylin  SAAR282201LC; Merck Chemicals (Pty), 
Ltd Gauteng  
Monoclonal Anti-insulin  K5355, Dako, North America, Inc  
Normal Goat Serum  -  
Normal Horse Serum  -  
Orange G  Merck Cas: 1936-15-8  
Oil red O solution (0.2% isopropanol) Merck chemicals (Pty), Ltd. 01391, 
Oxalic acid  BDH Chemical Ltd Cat: 10174  
Phosphate Buffer solution  Merck Cas: P5358  
Periodic acid  Merck Cas: P7875  
Phosphotungstic acid  Merck Cas: P4006  
Polyclonal Anti-glucagon  Dako, North America, Inc. A0564, 
Ponceau de xylidine  Merck- P2395  
Potassium permanganate  BDH Chemicals, Cat: 10217  
Schiff reagent  Science World Batch: 08-01-127  
Silver nitrate  Merch chemicals Pty, Ltd Cat: 576 50 40 DC  
Sodium hydroxide  Merck Cas: 8045  
Strong ammonia (25%)  Merck Chemicals, Pty Ltd Wadeville, 
Gauteng  
Sulfuric acid  Merck Cas: 339741  
Tris Buffer solution  Merck Cas: T5912  
Vector Laboratories ABC Kit  Vector Laboratories PK6100  
Vector Laboratories ABC AP alkaline 
phosphatase mouse IgM kit  
Vector Laboratories Ak-5010  
Xylene  Merck Cas: 214736  
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Materials  Company  
Histology machinery 
Axiocam 105 Carl Zeiss, AG, Oberkom, Germany 
Embedding table  Leica EG 116 Embedder (SMM instruments. 
Johannesburg  
Incubator  Model IH-150; Gallenkamp  
Gilson pipettes 10, 100, 200 and 1000 μL  
Leica CM1850 UV Cryostat microtome  SMM instruments,  
Leica Autostainer XL  Leica ST 5010; Serial number 1732/02.2007  
Leica RM 2125 rotary microtome  Cat no. 045737989, SMM instruments, 
Germany  
Nikon Eclipse Ti Automated scanning 
microscope  
Nikon Instruments Inc. Walt Whitman Road 
Melville. New York  
Nikon Microscope camera  Nikon Digital Sight DS-Fic. Nikon 
corporation. Japan 
Incubator (Oven) Model: M53C. serial number 9513249  
Tissue processor  Shandon Elliot Duplex Processor 
OptoLaboratory. Cape Town  
Zeiss ® Axioskop 2 light microscope Carl Zeiss, AG, Oberkom, Germany 
Software used  
Nikon NIS Imaging Software v4.40  Nikon Instruments Inc. Copyright 1991-2015  
ImageJ National institute of Health 
STEPanizer © stereology tool (2017) Version 
1.8 jar 
Stephan Tschanz (2017) 
Statistica Version 13.2  Dell. 2014. USA  
Zen (2012) blue edition Version 1.1.2.0 
software  
Carl Zeiss Microscopy. Oberkochen  
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Addendum C: Harvest procedure 
 
Table 2: Description of tissue harvesting, storage and embedding. 
Tissue Method Storage  Embedding 
Pancreas Once the pancreas was 
removed from its attachments 
in the abdominal cavity; it was 
weighed. The pancreas was 
halved, one portion was fixed 
in formalin and the other was 





Snap frozen in 
liquid nitrogen and 
stored in -80˚C 
freezer. 
The excess fat was 
removed from the 
pancreas and the whole 
specimen was processed 
and embedded in wax 
blocks.  
Liver The liver was removed by 
severing its attachments in the 
abdomen. It was weighed, and 
the left lateral lobe was 
removed for processing to wax 
blocks. The middle lobe was 





room temperature.  
Tissue was snap 
frozen in liquid 
nitrogen in zip lock 
packets and stored 
in -80˚C freezer.  
Tissue was trimmed to 
fit into the cassette, 
processed and 
embedded in wax.  
Frozen tissue was cut, 
mounted with mounting 
media and allowed to 
freeze solid in liquid 
nitrogen before 
sectioning.  
Kidney  The right kidney was removed 
from the animal and weighed. 
The kidney was cut in cross 
section and each half, halved 
once more so that four equal 
pieces were produced. The two 
middle halves were processed 





Two halves of kidney 
were trimmed and 
placed in cassette for 
processing. The tissue 
was aligned in such a 
way that the inside of 
the kidney would be 
visible 
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Table 3: The location, number and stain used for the pancreas, liver and kidney.  
Organ Sample 
location 









7 per group H&E  















7 per group H&E 
Masson’s Trichrome 
Gordon and Sweet’s Reticulin 
impregnation 
Middle lobe Liquid 
nitrogen 
20   










7 per group H&E 
Periodic acid Schiff 
* 
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Addendum D: Green Rooibos supplement preparation and dosage calculation 
 
Materials 
• 5 ml Red jelly (Moir’s)  
• 10 ml Gelatin  
• 35 ml water 
• 600 mg aspalathin enriched green rooibos extract powder (Afriplex) 
 
Methods 
• Dissolve 4 g of strawberry jelly and 4 g of gelatine in 25 ml of boiling water  
• Determine the dosage of Afriplex GRT™ per animal and add to mixture. 
• Place the mixture on a magnetic stirrer to ensure it does not set.  
• Use a repetitive pipet to transfer 1 ml of the mixture into an ice-block container and 
allow it to set.  
• Keep the jelly blocks refrigerated in sealed containers protected from light. 
 
Dosage (Adapted from Maqeda, 2018) 
Each animal was given Afriplex GRT™ according to their average body mass per week. 




If the rat weighed 275 g, their mass was multiplied by the concentration of Afriplex GRT™ 
(60 milligrams per kilogram body mass) and divided by 1000 (to cancel out the kilogram). This 
value was then multiplied by the total volume of Afriplex GRT™ required per week. The value 
in milligram per milliliter will be the amount to add to the jelly mixture 
 
275 𝑔 𝑏𝑜𝑑𝑦 𝑚𝑎𝑠𝑠 𝑜𝑓 𝑎𝑛𝑖𝑚𝑎𝑙 𝑋 60 𝑚𝑔 𝐴𝑓𝑟𝑖𝑝𝑙𝑒𝑥 𝐺𝑅𝑇(𝑇𝑀)
1000
𝑋 25 𝑚𝑙 
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Addendum E: Afriplex GRT™ high performance liquid chromatography polyphenol 
analysis and certificate of analysis 
 
Table 4: Afriplex GRT™ high performance liquid chromatography polyphenol analysis. 
Nq: not quantifiable 
[compound] (g compound/ 100 g Soluble Solids) 





Ferulic acid nq 
Vitexin 0.338513 
Isovitexin 0.298022 










Figure 1: Certificate of analysis of Afriplex GRT™ extract. 
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Addendum F: Tissue processing 
 
Methods 
After 36-48 hours in neutral buffered formalin the tissue was processed using the Shannon 
Eliot Duplex automatic tissue processor (Opto Laboratory, Cape Town) for 12 hours according 
to the following protocol.  
• Tissue was trimmed and placed into labelled plastic embedding cassettes with metal 
lids. 
• Cassettes placed into processing basket and into the machine. 
Table 5: Automated tissue processing protocol. 
Step  Solution  Time (min)  Temperature (ºC)  
1  70% Ethanol  30  40  
2  80% Ethanol  30  40  
3  95% Ethanol  45  40  
4  95% Ethanol  45  40  
5  100% Ethanol  45  40  
6  100% Ethanol  45  40  
7  100% Xylene  45  40  
8  100% Xylene  45  40  
9  Paraffin  30  58  
10  Paraffin  30  58  
11  Paraffin  30  58  
12  Paraffin  30  58  
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Addendum G: Hematoxylin and eosin (H&E) staining procedure 
 
The H&E stain was done using the Leica Autostainer XL (Leica ST5010, 1732/07.2007). The 
slides were placed into a plastic rack and then into the autostainer. A pre-programmed 
procedure was followed as shown below.  
• Remove slides from the incubator 
• Place slides into a plastic staining rack 
• Place rack into autostainer 
• Start the autostainer 
Table 6: Automated H&E staining protocol using the Leica Autostainer XL. 
Step  Solution  Time 
(minutes) 
Repetitions  
1  Xylene  10  2  
2  Ethanol (99%)  5  2  
3  Ethanol (96%)  2  1  
4  Ethanol (70%)  2  1  
5  Distilled water  5 sec  1  
6  Hematoxylin  8  1  
7  Running water  5  1  
8  Ethanol (1% acid alcohol)  30 sec  1  
9  Running water  1  1  
10  Ammonia (0.2%)  45 sec  1  
11  Running water  5  2  
12  Ethanol (96%)  10 dips  1  
13  Eosin  45 sec  1  
14  Ethanol (96%)  5  2  
15  Xylene  5  2  
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Addendum H: Double antibody labelling protocol 
 
Double Antibody labelling was performed as per the protocol by the South African Medical 
Research Council Biomedical Research and Innovation Platform): SOP No: ICC\B7-V01. 
 
Additionally, the following standard operating procedures were followed: 
• ICC\B8-V01 Vectastain Kit 
•  ICC\B14-V01 0.05M Tris Buffered Saline pH7.2 
•  ICC\B9-V01 Biotinylated Mouse Anti-IgG 
•  ICC\B16-V01 Normal Goat Serum 
•  ICC\B17-V01 Normal Horse Serum 
•  ICC\B18-V01 0.1M Phosphate Buffered Saline pH7.2 
•  ICC\B20-V01 Polyclonal Anti-Glucagon 
•  ICC\B17-V01 Monoclonal Anti-Insulin 
•  ICC\B27-V01 Liquid DAB+ Substrate Chromagen System 
•  ICC\B26-V01 Envision G/2 System/AP, Rabbit/Mouse Kit 
 
Table 7: List of reagents used for Double antibody labelling.  
Reagents  Quantity  
Polyclonal Anti-glucagon (rabbit) 
1:100  
1 μL anti-glucagon + 99 μL 0.1 M PBS = 100 μL/slide  
Biotinylated Goat Anti-Rabbit IgG  11.25 μL made up to 2.5 mL 0.05 M TBS pH 7.2  
Vectastain ABC Kit  5 mL distilled water + 1 drop A and 1 drop B  
DAKO Liquid DAB+ Chromogen  1 mL substrate buffer + 1 drop DAB chromogen=100 
μL/slide/10x  
Monoclonal Anti-Insulin (mouse) 
1:1 000  
5 μL 1:50 anti-insulin + 95 μL 0.1 M PBS = 100 μL/slide  
DAKO Envision Kit  
Rabbit/Mouse Link  100 μL/slide  
AP Enzyme (ENHANCER)  100 μL/slide  
Permanent Red Chromogen 
Substrate Working Solution  
10 μL permanent red chromogen + 1 000 μL permanent 
red substrate buffer = 100 μL/slide (10 slides)  
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Table 8: Double antibody labelling protocol. 
Double antibody labelling protocol: anti-glucagon and anti-insulin 
Step Description  Time 
(minutes) 
Temperature 
1  Dewax sections through xylene and alcohol to water -  RT 
2  Rinse slides in staining jar with distilled water  -  RT 
3  Block tissues for endogenous peroxidase with a 3% 
hydrogen peroxide (H2O2)  
5 RT 
4  Rinse slides with 0.05 M TBS pH 7.2  5  RT 
5  Dry around the section   RT 
6  Add 1:20 dilution of normal goat serum (NGS) to slides 
in a moisture chamber 
20 RT 
7  Blot excess serum  -  RT 
8  Add 100 μL anti-glucagon primary antibody 1:100 to 
sections in a moisture chamber  
30 RT 
9  Jet wash with 0.05 M TBS pH 7.2 and rinse in staining 
jar in 0.05 M TBS pH 7.2  
5  RT 
 Make up Biotinylated Anti-Rabbit igg and Vectastain)  -  RT 
10  Dry around sections and add Biotinylated Anti-Rabbit 
IgG 1:200 to slides in moisture chamber  
30  RT 
11  Jet wash with 0.05 M TBS pH 7.2 and rinse in staining 
jar in 0.05 M TBS pH 7.2  
10  RT 
12  Dry around sections and add Vectastain to slides in 
moisture chamber  
60  RT 
13  Jet wash slides with 0.05 M TBS pH 7.2 and rinse in 
0.05 M TBS pH 7.2 in staining jar.  
10  RT 
14  Dry around sections and add Liquid DAB + Chromogen 
solution to slides on a rack over the sink  
5  RT 
15  Jet wash slides with distilled water and rinse with 
distilled water in a staining jar  
5  RT 
16  Rinse slides in 0.05 M TBS pH 7.2 in staining jar  5  RT 
17  Dry around section and add normal horse serum (NHS) 
1:20 to slides in a moisture chamber  
20  RT 
18  Blot excess serum  -  RT 
19  Add 100 μL anti-insulin 1:10 000 to sections in moisture 
chamber  
Overnight  4 ºC 
20  Remove slides from the refrigerator and allow slides to 
reach room temperature  
-  RT 
21  Jet wash with 0.05 M TBS pH 7.2 and rinse in staining 
jar in 0.05 M TBS pH 7.2  
5  RT 
22  Dry around sections and add 100 μL Rabbit/Mouse 
(LINK) to slides in moisture chamber  
30  RT 
23  Jet wash with 0.05 M TBS pH 7.2 and rinse in staining 
jar in 0.05 M TBS pH 7.2  
10  RT 
24  Dry around sections and add 100 μL AP Enzyme 
(ENHANCER) to slides in moisture chamber  
30  RT 
25  Jet wash slides with 0.05 M TBS pH 7.2 and rinse in 0.05 
M TBS pH 7.2 in staining jar.  
10  RT 
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Step Description  Time 
(minutes) 
Temperature 
26  Dry around sections and add Substrate Working Solution 
to slides on a rack Check progress under microscope. 
Carcinogenic wear gloves.  
3-5  RT 
27  Jet wash slides with distilled water and rinse in distilled 
water in staining jar  
5  RT 
28  Counterstain with haematoxylin  2-4  RT 
29  Rinse well in tap water and leave to blue in tap water 30 RT 
31  Dry completely on paper towel (section facing upwards)  -  RT 
32  Mount slides in DPX  -  RT 
 
Controls 
Method control- Kidney tissue from a unrelated study (same fixative) 
External control-pancreas tissue unrelated study 
Internal control- pancreas tissue from control group 
  
Results  Label  
α-cells  Brown  
β-cells  Red/pink  
Tissue Blue/purple 
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Addendum I: Oil red O staining procedure (adapted from Bancroft and Gamble., 2008) 
 
Frozen liver and pancreas sections were stained with Oil red O stain to determine lipid 
accumulation. Oil red O demonstrates neutral lipids in fresh or frozen tissue and generally 
stains lipids orange-red (Saxena, 2010). Serial sections were prepared on positively charged 
microscope slides and stained with Oil Red O in dextrin for 20 minutes. Lastly, they were 
counterstained with 50% crystal violet for 1 minute. The Oil Red O stains makes it possible to 
identify lipid deposits in the tissue and the fatty accumulation may be quantified based on 
colour intensity using specialized morphometric techniques. Additionally, an H&E stain was 
done on frozen sections to assist in the identification and morphometry of the tissue. For 
optimum images, photographs need to be taken within 24-hours, but the stain is stable for up 
to three months. 
 
Table 9: Solutions used for Oil red O staining procedure.  
Solutions Quantity 
Oil Red O solution  
Oil red O 0.9 g 
Absolute isopropyl alcohol 180 ml 
Stir and leave overnight  
Dextrin solution  
Dextrin 1.2 g 
Distilled water 120 ml 
Working solution  
Oil Red O solution  180 ml 
Dextrin solution  120 ml 
Allow to stand for a day or more. Stable for months, filter before use.  
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Table 10: Protocol used for Oil red O staining. 
 
 
Furthermore, a manual H&E protocol was used on frozen tissue to assist morphological 
identification at the same tissue level. Tissue was mounted on positively charged microscope 
slides, fixed in 10% neutral buffered formalin (NBF) for 10 minutes and stained with 
haematoxylin for 10 minutes. The slides were rinsed and soaked in water. Subsequently, they 
were stained with eosin for two minutes. Lastly, the tissue was rehydrated to xylene and 
mounted with DPX. 
Controls 
Method control- liver tissue from unrelated study 
External control -intraperitoneal fat attached to muscle 
Internal control -tissue from control study group  
Step Description  Time 
(minutes) 
Temperature 
1 Remove the slides from the refrigerator and rest to each 
room temperature  
- (-4 ºC) to 
(±25 ºC). 
2 Pack the slides in a staining rack and stain in Oil Red O-
Dextrin for  
20 RT 
3 Rinse the slides in running tap water until water is clear. 2-3 RT 
4 Stain the slides in 50% Crystal violet  1 RT 
5 Rinse the slides in running tap water until water is clear. 2-3  
6 Air dry the slides until most of the water has run off.   
7 Apply coverslips to the slides with aqueous mounting 
media 
  
8 Seal the edges of the coverslip with clear nail varnish and 
allow to dry. 
  
9 For optimum analysis slides should be analysed within 
24-hours but this stain has been found to be stable ±3 
months after which significant colour leaching is seen. 
  
10 Warning: Do not expose the slides to alcohol, xylene or 
DPX as it will leach out the Oil red O stain as it digests 
fat.  
  
Results of Oil red O Label 
Lipids Orange-red 
Nuclei and tissue Blue purple 
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Addendum J: Masson’s trichrome 
 
Masson’s trichrome stain was performed to assess the degree of fibrosis within the liver.  
 
Table 11: Masson’s trichrome stain. 
Solutions Reagents Quantity 
Acetic acid water Glacial acetic acid  2 ml 
 Distilled water  1000 ml 
Masson Fuchsin Ponceau-Orange 
G (MFPOG)(Stock solution) 
Ponceau de Xylidine 
(Ponceau Red) 
2 g 
Acid Fuchsin 1 g 
Orange-G  2 g 
Acetic acid water 
(Working solution) 
300 ml 
Working solution MFPOG MFPOG  10 ml 
Acetic acid water  90 ml 
Light Green solution 0.1% Light Green  0.1 g 
Acetic acid water - 100 
ml 
100 ml 
5% Phosphotungstic acid Phosphotungstic acid  5 g 
Distilled water 100 ml 
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Table 12: Staining procedure for Masson’s trichrome. 
Step Description  Time 
(minutes) 
1 Deparaffinize sections (Xylene x2, graded alcohols 99, 96 & 
70% twice each). Wash in tap water. Place in distilled water. 
 
2 Stain with Mayers Haematoxylin.  5 
3 Place in tap water for 3 minutes until dark blue. 3 
4 Rinse in distilled water.  
5 Stain the sections in Fuchsin Ponceau-orange G solution  15 
6 Rinse in acetic acid water.  
7 Immerse in 5% phosphotungstic acid solution  5 
8 Rinse in acetic acid water. 1 
9 Stain in light green solution. 20 
10 Treat with acetic acid water  5 
11 Dehydrate as usual.  
12 Mount coverslip with DPX.  
 Results Label 
 Nuclei Purple black 
 Parenchyma  Orange red 
 Collagen  Green blue 
 
Controls 
Method control- liver tissue unrelated study (same fixative) 
External control skin 
Internal control-tissue from control study group 
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Addendum K: Gordon and Sweet’s silver impregnation protocol (Adapted from Bancroft 
& Gamble., 2008 
 
The Gordon and Sweet’s stain was used on liver tissue to evaluate the structural integrity.  
 
Table 13: Gordon and Sweet’s staining solutions 
Solutions.  Quantity  
Acidified Potassium permanganate XE  
0.5% Potassium permanganate  95 mL  
3% Sulphuric acid  5 mL  
Silver solution  
10% Aqueous silver solution 5 ml 
Ammonia Drop  
3% sodium hydroxide 5 ml 
Make up 5 mL of 10% aqueous silver nitrate. Add strong ammonia drop by drop until the 
precipitate is just dissolved. Add 5 mL of 3% sodium hydroxide. Then add strong ammonia 
drop by drop until the resulting precipitate is almost completely dissolved. Make up to 50 mL 
using distilled water then pour into a clean coplin staining jar. NOTE: If too much ammonia 
is added there is a great loss of sensitivity.  
2% aqueous oxalic acid  
Oxalic acid (analytical)  2 g  
Distilled water  100 mL  
Light green solution 0.1%  
Light green  0.1 g  
Acetic acid water 0.2%  100 mL  
4% aqueous iron alum  
Iron alum (Ferric ammonium sulphate)  4 g  
10% formalin  
Formaldehyde 40 g/L  10 mL  
Distilled water  90 mL  
Sodium thiosulphate (HYPO)  
Sodium thiosulphate  2 g  
Distilled water  100 mL  
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Table 14: Gordon and Sweet’s staining procedure. 
Step Description  Time 
(minutes) 
Temperature 
1 Dewax tissues from xylene, through alcohols to 
water 
 RT 
2 Oxidize in acidified potassium permanganate 3  RT 
3 Rinse with distilled water  RT 
4 Decolorize with 2 % oxalic acid 1 RT 
5 Rinse with distilled water  RT 
6 Mordant with 4 % iron alum 10 RT 
7 Rinse with distilled water  RT 
8 Impregnate in ammonical silver solution 11 seconds RT 
9 Rinse quickly with distilled water  RT 
10 Reduce with 10 % aqueous formalin  RT 
11 Wash with tap water 2 RT 
12 Rinse in distilled water  RT 
13 Fix 2 % aqueous sodium thiosulphate  2 RT 
14 Wash with water 2 RT 
15 Counterstain with light green solution 30 seconds RT 
16 Rehydrate with alcohols (5 dips each) to xylene (2 
minutes) and coverslip with DPX 
 RT 
Results  Label 




External control -skin 
Internal control- control tissue from the control study group 
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Addendum L: Periodic acid Schiff stain 
Table 15: Periodic acid Schiff staining solutions. 
Solutions.   Quantity  
0.5% Periodic acid solution    
 Periodic acid  0.5 g  
 Distilled water  100 mL  
Schiff solution  Drop wise 
Mayer’s Haematoxylin   Counterstain  
 
Table 16: Periodic acid Schiff staining protocol. 
Step  Description Time 
(minutes) 
Temperature 
1  Deparaffinize and hydrate to water   RT 
2  Oxidize tin 0.5% periodic acid solution  5 RT 
3  Rinse in distilled water   RT 
4  Cover each section with Schiff reagent  
(tissue becomes light pink in colour)  
15 RT 
5  Wash in lukewarm water (tissue sections turn a dark 
pink colour)  
5 RT 
6  Wash tissue sections in running tap water  5 RT 
7  Dehydrate and mount using DPX mounting medium   RT 
Results: Stain  
Glycogen. mucin and basement membranes  Magenta  
Nuclei Purple  
Cytoplasm  Pink  
 
Schiff Reagent viability.  
To test Schiff reagent, pour 10 mL of 37% formalin into a watch glass. Using a pasteurized 
plastic pipette add a few drops of Schiff reagent. Schiff will rapidly turn a red-purple colour if 
useable. If colour change happens over a longer period of time, this indicates a deteriorating 
Schiff reagent. The colour produced will be a dark blue-purple. 
 
Controls 
Method control- kidney from an unrelated study (same fixative) 
External control Colon 
Internal control- tissue from study control group   
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Addendum M: Macros produced to perform automated and semi-automated analysis of 
the tissues using ImageJ. 
Pancreas 
Pancreatic section area  
run("RGB Stack"); 




Islet, α- cell and Β-cell areas 




//Measure alpha area 
run("Threshold..."); 
waitForUser("set the threshold and press OK, or cancel to exit macro");  
// pauses the execution and lets you access ImageJ manually  
 // as long as you don't press OK, which resumes the macro execution  
run("Measure"); 
//Measure beta cell area 
//Trace beta cell area 
run("Threshold...");              
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Addendum N: Randomization technique for the pancreas, liver and kidney 
 
Pancreas 
All pancreatic islets which were completely in view were analysed. 
As tissue differences existed due to sharing of the tissue for molecular and physiological tests. 
To control for this, an equal number of pancreatic islets was analysed per group (n=400). Tod 
determine this, the data per animal was moved to a new Microsoft Excel spreadsheet. 
Pancreatic islets which lacked α- cells or Β-cells were excluded. Thereafter, if groups had more than 
400 islets, a random number generator was applied to each group. This was done by assigning numbers 
to each pancreatic islet which fell within the criteria. Fifty-seven numbers were randomly produced by 
the random number generator, selected and transferred to a new spreadsheet. Means were determined 
per group where after statistical analysis was performed. 
  
Liver 
• The liver tissue section was macroscopically divided into four regions by five parallel 
lines 4 mm apart (Figure 4.6). 
• Three images per region were captured and stored in a single folder 
• Randomly every second image was selected and moved to a new folder until 10 images 
per animal were selected. 
 
Kidney 
• Once the kidney was photographed using the Nikon system (Table 4.2) all images were 
stored in a single file. 
• Images containing glomeruli were selected and moved to a new folder. 
• Every fourth image was selected, and measurements of the glomeruli, Bowman’s 
capsule and proximal convoluted tubules was completed. 
• glomeruli were rejected if: 
o Not surrounded by three similar proximal convoluted tubules 
o Not completely in view (cut by image borders) 
 
  
Stellenbosch University  https://scholar.sun.ac.za
131 
 
Addendum O: Supplementary statistical analysis  
Table 17: Body and organ mass 







354.21±19.76 319.71±7.95 365.86±20.02 310.43±12.12   
Pancreas 
mass 
0.86±0.2 0.51±0.047 0.74±0.15 0.44±0.04   
Liver 
mass 
10.93±0.68 9.65±0.17 15.47±0.97 11.51±0.64   
Kidney 
mass 
1.05±0.05 0.87±0.02 0.95±0.03 0.79±0.04   
*Values based on a one-way ANOVA between groups 
**Values based on two-way ANOVA between treatment & diets 
Pancreas 
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Table 18: Supplementary statistical analysis of the pancreas (Mean ± standard error of the mean). 
Mean C GRT HFD HFD-GRT Two-way 
ANOVA 
p-value** 
Section area 69573594±4187661a 52941171±7561923ab 40938268±8439985b 33252298±4225573b 0.058(T) 
0.012(D) 
0.356 (D*T) 









Β-cell area 6475.97±974.27 6461.62±437.10 5403.25±494.20 3588.24±820.97 0.21(T) 
0.01(D) 
0.22(D*T) 
α- cell area 1031.28±140.87 1102.43±222.68 887.39±142.62 648.44±107.39 0.62(T) 
0.068(D) 
0.355(D*T) 
Islet volume level 1 4.84±1.97 4.11±1.19 6.24±4.18 6.42±2.74 p=.01 
Islet volume level 2 6.16±3.26 6.53±3.41 10.43±8.08 6.71±2.28 p=0.69 
Islet volume level 3 4.92±2.34 3.54±1.31 5.30±4.62 6.58±2.45 p=0.00 
Islets area (μm2) per tissue section area 
(μm2) (%) 
0.019±0.004 0.053±0.028 0.038±0.013 0.024±0.004 0.55(T) 
0.75(D) 
0.14(D*T) 
Islet number per tissue section area in 
mm2 
0.85±0.11 1.29±0.18 1.40±0.11 1.91±0.75 0.24(T) 
0.151(D) 
0.934(D*T) 
α-cells (%) 12.83±1.21 12.84±1.22 13.52±1.46 15.69±1.55 0.21(T) 
0.43(D) 
0.44(D*T) 
β-cells (%) 72.91±3.82 69.72±2.34 74.81±1.51 69.47±3.72 0.21(T) 
0.43(D) 
0.44(D*T) 
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α-cells per islet area (%) 8.58±0.67 8.59±1.32 8.23±1.22 9.22±1.05 0.65(T) 
0.90(D) 
0.66(D*T) 
β-cells per islet area (%) 52.83±3.07 49.87±3.05 52.64±2.35 46.23±4.00 0.55(T) 
0.15(D) 
0.60(D*T) 
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Supplementary data for the liver 
Table 19: Supplementary statistical analysis of the liver 
Mean  C GRT HFD HFD-GRT p-value 




























Volume of steatosis: fat 






















































































Figure 2: Liver sinusoidal area as determined using image processing.  
On the H&E slides in the C- and GRT groups the sinusoid area is easily discernable as very 
little fat is present. The purpose of this graph is to account for the difference between tissue 
area and fat area which would be the sinusoidal area. Therefore, in the C- and GRT groups the 
sinusoids account for about 40-43% of the area while the hepatic tissue 60-67% accounts for 
the remainder. 
  




Table 20: Kidney supplementary data. 












































































11.76±1.05 11.82±0.42 10.85±0.93 10.02±0.64 0.63 
0.10 
0.57 
PCT wall area 2241.94±299.
03 
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Table 21: Histopathologist pancreas, liver and kidney evaluation. 
  











































































































































































































































































































































Control  Mean 1 0.333 0 0 0 0 1.7 0 0 0 0 0 0 1 1 1 1 0 0 1 
% 1 33.33 0 0 33 0 33 0 0 0 0 0 0 100 100 67 33 0 0 100 
GRT Mean 0 0.667 0 0 1 0 1.7 0 0 0 0 0 0.333 1 1 1 2 0 0 0.7 
% 0 66.67 0 0 67 0 33 0 0 0 0 0 33.33 100 67 67 67 0 0 67 
HFD Mean 0.67 0.333 0 0 1 0 4 1 0 1 0.667 0 0 0.67 0 0 2 0.67 0 1 
% 66.67 33.33 33 0 67 0 80 67 0 100 66.67 0 0 66.67 33 0 67 66.67 0 100 
HFD-GRT Mean  0.33 0.333 0 0 0 0 3 0 0 0.7 1 0 0 0 0 0 1 0 0 0.7 
% 33.3 33.33 0 0 33 0 60 33 0 67 100 0 0 0 33 0 33 0 0 67 
p-value  <0.05 n.s n.s n.s n.s n.s <0.05 n.s n.s n.s n.s n.s n.s n.s n.s n.s n.s n.s n.s n.s 
*n.s= non-significant (statistically) 
<0.05= statistically significant  
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Table 22: Non-alcoholic fatty liver disease activity score observers score sheet. 
 Study 












4 1363/16 0   0 0 0 0 0 0 0 
4 1381/16 0   0 0 0 0 0 0 0 
2 1537/16 0   0 0 0 0 0 0 0 
3 1557/16 0   0 0 0 0 0 0 0 
1 1533/16 0   0 0 0 0 0 0 0 
5 1541/16 0   0 0 0 0 0 0 0 
5 1385/16 0   0 1 1 0 0 1 0 
GRT 
1 1474/16 0   0 0 0 0 0 0 0 
4 1486/16 0   0 0 0 0 0 0 0 
2 1509/16 0   0 0 1 1 0 1 0 
1 1545/16 0   0 0 0 0 0 0 0 
2 1553/16 0   0 0 0 0 0 0 0 
2 1505/16 0 2 1 0 2 1 0 1 0 
4 1549/16 0   0 0 2 1 0 0 0 
HFD 
3 1330/16 3 2 1 0 3 1 1 1 2 
1 1338/16 2 2 1 0 2 0 1 1 2 
3 1396/16 1 2 1 0 0 0 0 0 0 
2 1521/16 3 3 1 0 2 1 1 1 2 
5 1529/16 3 2 1 1 2 1 1 1 2 
3 1400/16 3 2 1 0 3 1 0 0 2 
5 1525/16 2 2 1 0 0 1 1 1 1 
HFD 
GRT 
1 1513/17 2   1 0 2 0 1 0 1 
2 1478/16 3 3 1 0 3 1 1 1 2 
3 1517/16 2 1 1 0 2 1 0 0 2 
3 1569/16 1 1 1 0 1 1 0 0 1 
4 1466/16 3 2 1 0 2 1 1 1 2 
4 1561/16 3 2 1 0 1 1 1 0 2 
5 1565/16 2 2 1 1 3 1 0 1 1 
*Observer number: Five observers including the investigator
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Addendum P: Grading sheet provided to Non-alcoholic fatty liver disease scorers 
NAS summary 
Below is a summary of the main pathology topics you will score. Thereafter brief descriptions of 




Figure 3: Non-alcoholic fatty liver disease activity score steatosis grading. A) normal fatty 
change. B) mild fatty change. C) moderate fatty change and D) severe fatty change. 
Micrography by Jodie Layman. 
 
Grade: Starting at low magnification (4x) evaluate each animal e.g. 1385-16 from broader end to 
the tip of the tissue section for steatosis. Evaluate the tissue for small (microvesicular) and/or large 
(macrovesicular) vacuoles of fat in the grades described above and assign a score. 
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Location: Zone 3 (close to CV), Zone 1 (close to PT) and azonal (no distinct pattern). 
 
Figure 4: Non-alcoholic fatty liver disease activity score evaluating the location of steatosis. 
CV= central vein, PT= portal triad, consists of an artery, vein and bile duct form part of 
hepatic lobules, 1, 2, & 3 describe zones. Micrography by Jodie Layman 
 
Microvesicular and Macrovesicular steatosis 
Please describe the predominant area of steatosis: zone 3, zone 1 or azonal (no 
pattern) 
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Figure 5: Non-alcoholic fatty liver disease activity score microvesicular steatosis evaluation. 
Both images show microvesicular steatosis, the figure on the left being less severe than the 
right. The figure on the right has been labeled macrovesicular as the nucleus has been 
displaced and would most likely become macrovesicular. 
*Note some tissues present with a combination of the two. The score only wants to know if 
microvesicular was present or not. 
Microvesicular steatosis- lipid vacuoles less than 15μm which do not displace the hepatocyte 
nucleus, which is usually centrally located in the cell.  
Macrovesicular steatosis- lipid vacuoles which displace the nucleus and are larger than 15μm. 
When the many tiny microvesicular lesions break down to form one large vacuole. 
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*Please use the Masson’s trichrome stained slides of the same number to evaluate the tissue. 
 
Figure 6: Stages of fibrosis. Illustration of fibrosis as graded by the NAS score. Portal 
triad=red, green navy, Hepatic lobules= blue polygon, radiating hepatocytes= pink, light 
blue=fibrotic lesions. 
Categories 
Look for teal blue staining in the following regions: 
• Only Peri-sinusoidal or peri-portal- extensive blue staining around portal 
triads or in the sinusoids (blue lining along hepatocytes) 
• Mild Zone 3 (around the central vein) and around the sinusoids 
• Moderate staining involving zone 3 and around the sinusoids 
• Only around the portal triads 
• Perisinusoidal and periportal 
• Bridging- fibrosis which forms continuous bands (not isolated around portal 
triads or sinusoids but joins together) 
• Cirrhosis- blue staining throughout parenchyma of the liver 
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Lobular inflammation (Lobes of inflammation) (extra medullary haematopoiesis) 
Overall assessment of all inflammatory foci (purple, rod shaped to rounded structures) 
No foci   0   
<2 foci per 200X field 1   
2-4 foci per 200X field 2   
>4 foci per 200X field  3   
 
Microgranulomas (Small aggregates of macrophages) 
Absent 0  
Present 1  
 




Portal inflammation (Assessed from low magnification) 
None to minimal  0  
Greater than minimal  1 
 
*inflammatory foci around portal triads  
The following scoring grades are to define the types of inflammatory foci. Fat containing 
inflammatory foci (Lipogranulomas), congregates of pigmented (brown, red & purple) macrophages 
(Pigmented macrophages), collections of inflammatory cells only purple (Microgranulomas). 
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Figure 7: Inflammatory foci as evaluated by the NAS. A) An illustration of liver lobules 
showing the locations (zone one, two and three) as well as the type of inflmattory foci found 
in that region.  
 
Liver cell injury 
*This is specifically about the hepatocytes  
Ballooning* 
 None      0  
Few balloon cells    1  
Many cells/prominent ballooning  2  
*Look for cells that are swollen, possible nuclei displacement, lighter colour in the centre of cell 
compared to the cell border. 
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Figure 8: Hepatocyte ballooning as evaluated with the NAS score. Both images show 
hepatocyte ballooning outlined by dotted lines. 
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Addendum Q: Plagiarism report 
 
 
Figure 9: Plagiarism report. 
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